Comparison of the global prevalence and trend of human intestinal carriage of ESBL-producing Escherichia coli between healthcare and community settings: a systematic review and meta-analysis

Yihienew M Bezabih; Alemayehu Bezabih; Michel Dion; Eric Batard; Samson Teka; Abiy Obole; Noah Dessalegn; Alelegn Enyew; Anna Roujeinikova; Endalkachew Alamneh; Corinne Mirkazemi; Gregory M Peterson; Woldesellassie M Bezabhe

doi:10.1093/jacamr/dlac048

. 2022 Jun 2;4(3):dlac048. doi: 10.1093/jacamr/dlac048

Comparison of the global prevalence and trend of human intestinal carriage of ESBL-producing Escherichia coli between healthcare and community settings: a systematic review and meta-analysis

Yihienew M Bezabih ^1,^2,^✉, Alemayehu Bezabih ³, Michel Dion ⁴, Eric Batard ^4,⁵, Samson Teka ⁶, Abiy Obole ², Noah Dessalegn ², Alelegn Enyew ³, Anna Roujeinikova ⁷, Endalkachew Alamneh ⁸, Corinne Mirkazemi ⁸, Gregory M Peterson ⁸, Woldesellassie M Bezabhe ⁸

PMCID: PMC9160884 PMID: 35668909

Abstract

Objectives

The widespread intestinal carriage of ESBL-producing Escherichia coli (ESBL E. coli) among both patients and healthy individuals is alarming. However, the global prevalence and trend of this MDR bacterium in healthcare settings remains undetermined. To address this knowledge gap, we performed a comparative meta-analysis of the prevalence in community and healthcare settings.

Methods

Our systematic review included 133 articles published between 1 January 2000 and 22 April 2021 and indexed in PubMed, EMBASE or Google Scholar. A random-effects meta-analysis was performed to obtain the global pooled prevalence (community and healthcare settings). Subgroup meta-analyses were performed by grouping studies using the WHO regions and 5 year intervals of the study period.

Results

We found that 21.1% (95% CI, 19.1%–23.2%) of inpatients in healthcare settings and 17.6% (95% CI, 15.3%–19.8%) of healthy individuals worldwide carried ESBL E. coli in their intestine. The global carriage rate in healthcare settings increased 3-fold from 7% (95% CI, 3.7%–10.3%) in 2001–05 to 25.7% (95% CI, 19.5%–32.0%) in 2016–20, whereas in community settings it increased 10-fold from 2.6% (95% CI, 1.2%–4.0%) to 26.4% (95% CI, 17.0%–35.9%) over the same period.

Conclusions

The global and regional human intestinal ESBL E. coli carriage is increasing in both community and healthcare settings. Carriage rates were generally higher in healthcare than in community settings. Key relevant health organizations should perform surveillance and implement preventive measures to address the spread of ESBL E. coli in both settings.

Introduction

The widespread intestinal carriage of ESBL-producing Escherichia coli (ESBL E. coli) among patients and healthy individuals is alarming.¹ This is because ESBL E. coli can cause MDR infections that are difficult to treat. In healthcare settings it can cause serious hospital-acquired infections that have a 3-fold increased mortality compared with infections caused by non-drug-resistant E. coli strains.² In a community setting, it can lead to community-acquired MDR infections, such as recurrent urinary tract infections (UTIs), with an increased risk of morbidity.^3–6

In many studies, human faecal ESBL E. coli carriage prevalence was higher in hospital settings than in the community.^7–9 This could be related to the use of antibiotics, which is an independent risk factor for ESBL E. coli faecal colonization.^10–14 In addition, antibiotic-mediated dysbiosis and loss of gut colonization resistance could facilitate the transmission (person-to-person contact, food and water ingestion, environmental contact) and acquisition of ESBL E. coli in the hospital setting.

In our recent systematic review and meta-analysis that evaluated the prevalence of faecal carriage of ESBL E. coli among healthy individuals, we found a global community prevalence of 16.5%, showing a dramatic 8-fold rise over the last two decades.¹ Our findings were in line with the earlier studies that showed that the pooled prevalence of ESBL Enterobacteriaceae in the community (more than 90% of which is accounted for by ESBL E. coli¹⁰) was 14% in 2016.¹⁵

However, the global prevalence and trend over time of this MDR bacterium in healthcare settings remains undetermined. In addition, no prior study has compared global carriage rates among patients and healthy individuals. Hence, in this meta-analysis, we explored the global prevalence of human ESBL E. coli faecal carriage in healthcare settings and compared it with the values found in the community. Furthermore, as the acquisition of intestinal ESBL E. coli carriage could rise with increasing hospital stay,^9,14 we compared carriage rates among patients with varying duration of hospitalization and in individuals living in nursing care facilities.

Methods

This meta-analysis was conducted following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) 2020 checklist¹⁶ (Table S1, available as Supplementary data at JAC-AMR Online).

Data sources and search terms

The data sources were articles published between 1 January 2000 and 22 April 2021 and obtained by a systematic search in PubMed, EMBASE and Google Scholar. Four groups of search terms were used to find articles that determined the intestinal carriage rate of ESBL E. coli among patients admitted to healthcare settings (including individuals living in a nursing care facility): (i) Escherichia coli OR E. coli; (ii) extended spectrum β-lactamase OR ESBL; (iii) faecal OR faeces OR stool OR intestinal OR gastrointestinal tract; (iv) hospital OR hospital-acquired or admitted OR inpatient OR nursing home. These groups of search terms were then connected by the Boolean operator ‘AND’ to find papers that contained the terms anywhere in the article. Similarly, articles for the community setting were found using the above search terms except for the substitution of ‘community OR community-acquired’ in place of ‘hospital OR hospital-acquired or admitted OR inpatient OR nursing home’. For the healthcare setting, we retrieved a total of 1239 articles (328, 631 and 280 articles indexed in PubMed, EMBASE and Google Scholar, respectively) for further screening. For the community setting, we obtained a total of 590 articles (129, 181 and 280 articles indexed in PubMed, EMBASE and Google Scholar, respectively). The reference lists of the included papers were also checked to identify relevant studies. Screening of the articles by their titles and abstracts was performed by two authors (Y.M.B. and W.M.B.), and one author (A.B.) helped in reaching a consensus with any discrepancies.

Study selection: inclusion and exclusion criteria

Studies that determined the prevalence of ESBL E. coli carriage among patients (healthcare settings) or healthy individuals (community setting) of any age were eligible. Patients in the healthcare settings were defined as individuals who were kept at the emergency department or admitted to wards, ICU or a nursing care facility for any kind of treatment or care. Healthy individuals were defined as asymptomatic individuals living in the community, including those who visited a health facility for a routine wellness check-up, vaccination, antenatal care, pre-international travel screening, or transrectal biopsy screening for prostate cancer. In this manuscript, the terms ‘healthy individuals’ and ‘asymptomatic individuals’ were interchangeably used to describe individuals living in the community setting, and do not imply the absence of comorbidities or symptoms of illness. We used the term ‘stool sample’ for faecal samples collected either by the routine stool or rectal sampling.

We made four categories of study subjects by the duration of contact with a healthcare setting at the time of stool sampling: (i) healthy individuals (in the community); (ii) admitted <48 h; (iii) admitted ≥48 h; and (iv) living in nursing care facilities. We considered healthy individuals as having zero time of contact in a healthcare setting, whereas individuals living in nursing care were considered to have an indefinite time of contact. We categorized patients as ‘admitted <48 h’ if the faecal carriage rate in these patients was determined using a stool sample that was taken at admission or within 48 h of hospital admission. Participants were categorized as ‘admitted ≥48 h’ if the prevalence was determined from a stool sample taken after 48 h of admission, or from serial culturing from admission till discharge, or if the time of sampling was not specified.

We included original articles written in English and excluded case-control studies, reviews and conference abstracts. Studies that reported the prevalence of faecal ESBL E. coli among outpatients with recurrent UTI were excluded due to disproportionately high intestinal carriage rates of ESBL E. coli in such patients.^17,18 We have also excluded studies that determined ESBL E. coli carriage rates in returning travellers from countries with a high prevalence or among household contacts of colonized individuals; those that involved non-human study subjects or analysed non-faecal samples; and studies that measured the prevalence of faecal carriage of ESBL Enterobacteriaceae, but without bacterial species identification. Furthermore, we only included studies that used at least the double-disc synergy test (DDST) or PCR to confirm ESBL production and excluded those studies that relied on the routine antibiogram to detect resistance to cephalosporins. A flow chart showing the selection of articles pertaining to ESBL E. coli prevalence in both community and healthcare settings is shown in Figure 1.

Figure 1. — Selection of articles for the meta-analysis. Note: studies reporting the prevalence in both the community and healthcare settings were not discarded.

Data extraction and quality control

The prevalence of the human intestinal carriage of ESBL E. coli (the main outcome of interest) was calculated by dividing the total number of ESBL E. coli-positive individuals by the total number of individuals screened in each study. We also extracted data on the year of study, study design, nature of study participants, method of ESBL confirmation and study location (country and WHO region) (Table S2).

The quality of each study was assessed using the quality assessment tool for observational cohort and cross-sectional studies developed by the National Heart, Lung, and Blood Institute of the NIH¹⁹ (Table S3).

Data analysis

A random-effects meta-analysis using the DerSimonian and Laird method²⁰ was performed to obtain the global pooled prevalence for each setting (community and healthcare). Subgroup meta-analyses were performed by grouping studies using the WHO regions²¹ and 5 year intervals of the study period. For studies with a duration of more than 1 year (e.g. 2013–14), the approximate mean (2014) was taken as the year of study. The global trend of faecal ESBL E. coli carriage was demonstrated in two ways: (i) linear regression analysis and (ii) by using a pooled prevalence after articles grouped by 5 year intervals of the study period. The Freeman–Tukey arcsine methodology²² was used to stabilize the variance of raw proportions, and no studies with 0% or 100% proportions were excluded.²³ The measure of heterogeneity was the I² statistic.²⁰ Probability values less than 0.05 at a 95% CI were considered significant. Egger’s regression test was used to assess the presence of publication bias.²⁴ The OpenMeta (Analyst) software was used to perform the meta-analysis.²⁵ GraphPad Prism (version 8.0.2, San Diego, CA, USA) was used to create linear regression plots and bar graphs.

Results

Study characteristics and quality assessment

A total of 133 articles covering 73 318 participants were included in the meta-analysis (Figure 2, Figure S1). This included non-duplicate stool samples from 30 633 healthy individuals (65 articles in community settings) and 42 685 inpatients (68 articles in healthcare settings) (Figures 1 and 2, Figure S1). The majority of the studies in both the community (19/65, 29.2%) and healthcare (33/68, 48.5%) settings were from Europe (Figure 2). The study period of the included studies ranged from 2003 to 2018 for the community setting and 2002 to 2019 for the healthcare setting. All included studies were either cohort or cross-sectional studies with a fair to good quality (Table S2).

Comparison of global and regional prevalence in faecal ESBL E. coli carriage between the community and healthcare settings

Overall, the global and regional carriage rates generally appeared higher in healthcare than in community settings, although the 95% CIs overlapped in most of our analyses (Figure 3). Globally, the cumulative (2000–21) pooled prevalence of intestinal ESBL E. coli carriage in healthcare settings was 21.1% (95% CI, 19.1%–23.2%) compared with 17.6% (95% CI, 15.3%–19.8%) in the community settings (Figure 3a, Figure S1).

Figure 3. — The global and regional prevalence of human intestinal ESBL *E. coli* carriage. (a) The global pooled prevalence of faecal ESBL *E. coli* carriage in community and healthcare settings (forest plot in Figure S1). (b) Regional pooled prevalence of faecal ESBL *E. coli* carriage in the six WHO regions (forest plot in Figures S2 and S3). (c) A summary of global and regional human intestinal ESBL *E. coli* carriage with 95% CI as obtained from forest plots in Figures S1–S3. P values are the P values for heterogeneity.

In the community setting, by WHO region, the highest carriage rates occurred in South-East Asia (35.1%, 95% CI, 10.3%–60.0%), followed by the West Pacific (25.3%, 95% CI, 18.5%–32.1%), Africa (21.4%, 95% CI, 12.7%–30.1%) and Eastern Mediterranean (20.6%, 95% CI, 10.2%–31.0%). Europe (6.0%, 95% CI, 4.6%–7.5%) and the Americas (10.3%, 95% CI, 5.1%–15.6%) had the lowest reported ESBL E. coli colonization in the community (Figure 3b and c, Figures S2 and S3).

In contrast, in healthcare settings, the highest carriage rate was found in the Eastern Mediterranean (45.6%, 95% CI, 23.0%–68.2%), followed by South-East Asia (32.9%, 95% CI, 10.6%–55.1%), Africa (32.4%, 95% CI, 23.8%–41.0%) and the West Pacific (24.1%, 95% CI, 17.3%–30.8%), whereas the lowest colonization rate was seen in the Americas (4.9%, 95% CI, 0.6%–9.2%) and Europe (13.8%, 95% CI, 11.6%–16.0%) (Figure 3b and c, Figures S2 and S3).

Global and regional trends in prevalence of human intestinal ESBL E. coli carriage

Globally, and in each WHO region, the prevalence of human intestinal ESBL E. coli carriage showed a progressive increase from 2000 to 2021 (Figure 4a and c). Based on an estimation projection from linear regression analysis, and as shown in Figure 4(a), the global prevalence in the intestinal carriage of ESBL E. coli in the community was rising at a faster rate (a 1.5% yearly increase) than in the healthcare settings (1.3% annual rise). The global intestinal carriage rate of ESBL E. coli in the community increased 10-fold from 2.6% (95% CI, 1.2%–4.0%) in 2001–05 to 26.4% (95% CI, 17.0%–35.9%) in 2016–20 (Figure 4b and d, Figure S4), whereas in the healthcare setting, it increased from 7% (95% CI, 3.7%–10.3%) in 2001–05 to 25.7% (19.5%–32.0%) in 2016–20 (Figure 4b and d, Figure S5).

Analysis of correlation between human intestinal ESBL E. coli carriage rates and duration of stay in healthcare setting

An interesting finding, based on data from Europe, was that faecal ESBL E. coli colonization increased with increasing duration of contact/stay in a healthcare setting (Figure 5, Figure S6). Particularly, the prevalence of faecal ESBL E. coli colonization among patients admitted for more than 48 h was double the prevalence in healthy individuals, and in nursing care residents it was 3-fold higher than the prevalence in healthy individuals living in the community (Figure 5, Figure S6). Note, the other WHO regions had an insufficient number of studies for such analysis (Figure 2).

Figure 5. — Comparison of faecal ESBL *E. coli* carriage rate between healthy individuals and inpatients in Europe. Carriage rates among inpatients increased with increasing duration of stay in healthcare settings. Summary table (a) and bar graph (b) were based on the meta-analysis forest plot in Figure S6. P values are the P values for heterogeneity. In this subgroup analysis, the absolute numbers of participants (ESBL *E. coli* positive/total screened) in Europe were: community setting (887/15168), admitted <48 h (1254/11983), admitted ≥48 h (1445/16589) and nursing care (671/3892).

Discussion

In this study, based on 73 318 samples, 21.1% of inpatients in healthcare settings and 17.6% of healthy individuals in the community worldwide carried MDR ESBL E. coli bacteria in their intestines. While Europe and the Americas had the lowest colonization rate, all the other WHO regions had a carriage rate of above 20% in both community and healthcare settings. Over the past 20 years (2000–21), the global human intestinal ESBL E. coli carriage rate increased steadily in both healthcare and community settings. The upward trend was observed in each of the six WHO regions. The rate of increase appeared to be higher in the community than in healthcare settings, and colonization rates in the community were approaching values in the healthcare areas. The reason for a slower pace of rise in healthcare settings is unknown, although we think this could be due to the practice of standard precautions (note, contact precautions had no added benefit over standard precautions^26,27).

To our knowledge, this is the first study that has determined the global prevalence of the human intestinal carriage of ESBL E. coli in healthcare settings. We showed that at least one in five inpatients (21.1%) worldwide were carriers. The global carriage rate in the community (17.6%) was close to that reported in our previous publication (16.5%) (with the slight increase likely being the result of inclusion of more recent studies).¹ By WHO region, South-East Asia had the highest carriage rate (35.1%) in the community, while the Eastern Mediterranean had the highest carriage rate (45.6%) in healthcare settings.

Although confidence intervals overlap, the global intestinal ESBL E. coli carriage rate appeared higher in healthcare than in community settings (Figures 4a and 5a). Regardless, there was a clear and statistically significant higher carriage rate in healthcare than community settings in Europe (where the number of included studies was large enough). However, in certain regions, such as the Americas and South-East Asia (regions with the lowest number of studies) and the Western Pacific, the carriage rate in the community appeared to be higher than in healthcare settings (Figure 3b and c). These findings may be attributable to a spatial ‘maldistribution’ of the individual studies used to calculate the pooled prevalence. For example, for the Americas, the regional pooled prevalence appeared higher in the community than healthcare setting. This was because, in this region, most of the individual studies describing prevalence in the community were from South America (area of high colonization), whereas most of the individual studies that measured carriage rate in healthcare settings were from North America (area of low colonization). We confirmed this with further sub-meta-analysis by sub-region of the Americas, which showed ESBL E. coli colonization rates actually appeared higher in healthcare than community settings in South America (Figure S7) and North America (Figure S8) (values were statistically insignificant). Sub-meta-analysis findings by sub-regions of Europe and the West Pacific are provided in the supplementary materials (Figures S9–S13) for further comparison.

This study also found that prolonged stay in a healthcare setting was associated with an increase in human intestinal colonization by ESBL E. coli. We demonstrated this using data from Europe, where nearly half of all the included studies in the healthcare setting were undertaken. This finding is consistent with other studies which found that prolonged hospitalization was an independent risk factor for intestinal ESBL E. coli colonization.^9,14 Further, as antibiotics are commonly used in healthcare settings, the resulting gut dysbiosis (loss of gut colonization resistance) coupled with longer exposure to a high-prevalence healthcare setting (during a prolonged hospital stay) could provide a synergistic combination for increased acquisition.

This study has several limitations. First, as mentioned above, overestimation or underestimation of the global and regional pooled prevalence could result from the spatial ‘maldistribution’ of the individual studies included in the meta-analysis. For example, certain WHO regions might consist of countries with low and high colonization rates, and hence regional carriage rates in the community might appear higher than in healthcare settings. This occurs whenever a preponderance of studies included to calculate regional pooled prevalence for the community setting are from countries of high prevalence, while the studies used to measure regional carriage rates for the healthcare setting are from countries of low prevalence. A similar problem was seen when we grouped studies every 5 years to show the global trend. For instance, for the years 2016–20, the global cumulative prevalence in the community (26.4%) appeared higher than the values in healthcare settings (25.7%). However, our linear regression analysis found that the global human ESBL E. coli carriage in healthcare settings was always higher than in the community setting for all the years (2000–21) (Figure 4a). Hence, linear regression was used to offset such an intrinsic bias during the grouping of studies for pooled prevalence. In addition, there was a limited number of studies in some WHO regions.

Laboratory methods of ESBL identification improved over the years and this might have an influence on the rising trend in ESBL E. coli carriage. Besides, the techniques and sensitivity of the tests used might also differ in different regions of the world, leading to differences in ESBL E. coli prevalence. Publication bias (Figure S14), selection bias and the setting of studies (usually with interactions with the healthcare system) might have resulted in some overestimation of the prevalence in the community setting. For example, the total number of participants used to calculate the prevalence in the community included individuals who visited a health facility for a routine wellness check-up, but those individuals may have had prior interactions with a healthcare facility. The other limitation of this study is that the analysis was limited to the predominant ESBL-producing species—E. coli. The comparative prevalence of other Enterobacteriaceae needs to be addressed in future studies. Finally, the location of sample collection (community versus hospital versus nursing care) and the increased age of the nursing care residents may have introduced bias not accounted for in the calculation of the prevalence in the healthcare setting.²⁸

Conclusions

Global and regional human intestinal ESBL E. coli carriage is increasing in both community and healthcare settings. Carriage rates were generally higher in healthcare than in community settings. Based on data from Europe, where the most robust data were available, the faecal ESBL E. coli carriage rate among inpatients admitted for ≥48 h and nursing home residents was 2- and 3-fold, respectively, compared with the prevalence in healthy individuals living in the community. Key relevant health organizations should perform surveillance and implement preventive measures to address the spread of ESBL E. coli in both settings.

Supplementary Material

dlac048_Supplementary_Data

Click here for additional data file.^{(1.5MB, docx)}

Acknowledgements

Special thanks to Yohannes Gishen for his valuable support.

Funding

This study was conducted as part of our routine work.

Transparency declarations

None to declare.

Data sharing

All data are available in the manuscript or the supplementary materials.

Supplementary data

Tables S1–S3 and Figures S1–S14 are available as Supplementary data at JAC-AMR Online.

References

1. Bezabih YM, Sabiiti W, Alamneh Eet al. The global prevalence and trend of human intestinal carriage of ESBL-producing Escherichia coli in the community. J Antimicrob Chemother 2021; 76: 22–9. [DOI] [PubMed] [Google Scholar]
2. Melzer M, Petersen I. Mortality following bacteraemic infection caused by extended spectrum β-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J Infect 2007; 55: 254–9. [DOI] [PubMed] [Google Scholar]
3. Sakran W, Smolkin V, Odetalla Aet al. Community-acquired urinary tract infection in hospitalized children: etiology and antimicrobial resistance. A comparison between first episode and recurrent infection. Clin Pediatr (Phila) 2015; 54: 479–83. [DOI] [PubMed] [Google Scholar]
4. Chervet D, Lortholary O, Zahar J-Ret al. Antimicrobial resistance in community-acquired urinary tract infections in Paris in 2015. Med Mal Infect 2018; 48: 188–92. [DOI] [PubMed] [Google Scholar]
5. Ranjan Dash N, Albataineh MT, Alhourani Net al. Community-acquired urinary tract infections due to extended-spectrum β -lactamase-producing organisms in United Arab Emirates. Travel Med Infect Dis 2018; 22: 46–50. [DOI] [PubMed] [Google Scholar]
6. Al-Mayahie S, Al Kuriashy JJ. Distribution of ESBLs among Escherichia coli isolates from outpatients with recurrent UTIs and their antimicrobial resistance. J Infect Dev Ctries 2016; 10: 575–83. [DOI] [PubMed] [Google Scholar]
7. Ouchar Mahamat O, Tidjani A, Lounnas Met al. Fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae in hospital and community settings in Chad. Antimicrob Resist Infect Control 2019; 8: 169. [DOI] [PMC free article] [PubMed] [Google Scholar]
8. Ko YJ, Moon H-W, Hur Met al. Fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae in Korean community and hospital settings. Infection 2013; 41: 9–13. [DOI] [PubMed] [Google Scholar]
9. Kurz MSE, Bayingana C, Ndoli JMet al. Intense pre-admission carriage and further acquisition of ESBL-producing Enterobacteriaceae among patients and their caregivers in a tertiary hospital in Rwanda. Trop Med Int Health 2017; 22: 210–20. [DOI] [PubMed] [Google Scholar]
10. van den Bunt G, van Pelt W, Hidalgo Let al. Prevalence, risk factors and genetic characterisation of extended-spectrum β-lactamase and carbapenemase-producing Enterobacteriaceae (ESBL-E and CPE): a community-based cross-sectional study, the Netherlands, 2014 to 2016. Euro Surveill 2019; 24: 1800594. [DOI] [PMC free article] [PubMed] [Google Scholar]
11. Arnan M, Gudiol C, Calatayud Let al. Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. Eur J Clin Microbiol Infect Dis 2011; 30: 355–60. [DOI] [PubMed] [Google Scholar]
12. Zhang H, Zhou Y, Guo Set al. High prevalence and risk factors of fecal carriage of CTX-M type extended-spectrum β-lactamase-producing Enterobacteriaceae from healthy rural residents of Taian, China. Front Microbiol 2015; 6: 239. [DOI] [PMC free article] [PubMed] [Google Scholar]
13. Reuland EA, Al Naiemi N, Kaiser AMet al. Prevalence and risk factors for carriage of ESBL-producing Enterobacteriaceae in Amsterdam. J Antimicrob Chemother 2016; 71: 1076–82. [DOI] [PMC free article] [PubMed] [Google Scholar]
14. Kizilates F, Yakupogullari Y, Berk Het al. Risk factors for fecal carriage of extended-spectrum β-lactamase-producing and carbapenem-resistant Escherichia coli and Klebsiella pneumoniae strains among patients at hospital admission. Am J Infect Control 2020; 49: 333–339. [DOI] [PubMed] [Google Scholar]
15. Karanika S, Karantanos T, Arvanitis Met al. Fecal colonization with extended-spectrum β-lactamase–producing Enterobacteriaceae and risk factors among healthy individuals: a systematic review and metaanalysis. Clin Infect Dis 2016; 63: 310–8. [DOI] [PubMed] [Google Scholar]
16. PRISMA . http://prisma-statement.org/prismastatement/Checklist.aspx.
17. Jørgensen SB, Søraas A, Sundsfjord Aet al. Fecal carriage of extended spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae after urinary tract infection – a three year prospective cohort study. PLoS One 2017; 12: e0173510. [DOI] [PMC free article] [PubMed] [Google Scholar]
18. Rodríguez-Baño J, Alcalá JC, Cisneros JMet al. Community infections caused by extended-spectrum β-lactamase–producing Escherichia coli. Arch Intern Med 2008; 168: 1897–902. [DOI] [PubMed] [Google Scholar]
19. National Heart, Lung, and Blood Institute (NHLBI) . Study Quality Assessment Tools. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools.
20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–88. [DOI] [PubMed] [Google Scholar]
21. WHO Definition of Region Groupings . 2013. https://www.who.int/about/who-we-are/regional-offices.
22. Fazel S, Khosla V, Doll Het al. The prevalence of mental disorders among the homeless in Western countries: systematic review and meta-regression analysis. PLoS Med 2008; 5: e225. [DOI] [PMC free article] [PubMed] [Google Scholar]
23. Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health 2014; 72: 39. [DOI] [PMC free article] [PubMed] [Google Scholar]
24. Egger M, Davey Smith G, Schneider Met al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–34. [DOI] [PMC free article] [PubMed] [Google Scholar]
25. Wallace BC, Lajeunesse MJ, Dietz Get al. Open MEE: intuitive, open-source software for meta-analysis in ecology and evolutionary biology. Methods Ecol Evol 2017; 8: 941–7. [Google Scholar]
26. Tschudin-Sutter S, Lucet J-C, Mutters NTet al. Contact precautions for preventing nosocomial transmission of extended-spectrum β lactamase–producing Escherichia coli: a point/counterpoint review. Clin Infect Dis 2017; 65: 342–7. [DOI] [PubMed] [Google Scholar]
27. Maechler F, Schwab F, Hansen Set al. Contact isolation versus standard precautions to decrease acquisition of extended-spectrum β-lactamase-producing Enterobacterales in non-critical care wards: a cluster-randomised crossover trial. Lancet Infect Dis 2020; 20: 575–84. [DOI] [PubMed] [Google Scholar]
28. Mshana SE, Falgenhauer L, Mirambo MMet al. Predictors of bla_CTX-M-15 in varieties of Escherichia coli genotypes from humans in community settings in Mwanza, Tanzania. BMC Infect Dis 2016; 16: 187. [DOI] [PMC free article] [PubMed] [Google Scholar]
29. Medboua-Benbalagh C, Touati A, Kermas Ret al. Fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae strains is associated with worse outcome in patients hospitalized in the pediatric oncology unit of Beni-Messous Hospital in Algiers, Algeria. Microb Drug Resist 2017; 23: 757–63. [DOI] [PubMed] [Google Scholar]
30. Ouédraogo A-S, Sanou S, Kissou Aet al. Fecal carriage of Enterobacteriaceae producing extended-spectrum β-lactamases in hospitalized patients and healthy community volunteers in Burkina Faso. Microb Drug Resist 2017; 23: 63–70. [DOI] [PubMed] [Google Scholar]
31. Lonchel CM, Melin P, Gangoué-Piéboji Jet al. Extended-spectrum β-lactamase-producing Enterobacteriaceae in Cameroonian hospitals. Eur J Clin Microbiol Infect Dis 2013; 32: 79–87. [DOI] [PubMed] [Google Scholar]
32. Aklilu A, Manilal A, Ameya Get al. Gastrointestinal tract colonization rate of extended-spectrum β-lactamase- and carbapenemase-producing Enterobacteriaceae and associated factors among hospitalized patients in Arba Minch General Hospital, Arba Minch, Ethiopia. Infect Drug Resist 2020; 13: 1517–26. [DOI] [PMC free article] [PubMed] [Google Scholar]
33. Desta K, Woldeamanuel Y, Azazh Aet al. High gastrointestinal colonization rate with extended-spectrum β-lactamase-producing Enterobacteriaceae in hospitalized patients: emergence of carbapenemase-producing K. pneumoniae in Ethiopia. PLoS One 2016; 11: e0161685. [DOI] [PMC free article] [PubMed] [Google Scholar]
34. Falgenhauer L, Imirzalioglu C, Oppong Ket al. Detection and characterization of ESBL-producing Escherichia coli from humans and poultry in Ghana. Front Microbiol 2019; 9: 3358. [DOI] [PMC free article] [PubMed] [Google Scholar]
35. Isendahl J, Turlej-Rogacka A, Manjuba Cet al. Fecal carriage of ESBL-producing E. coli and K. pneumoniae in children in Guinea-Bissau: a hospital-based cross-sectional study. PLoS One 2012; 7: e51981. [DOI] [PMC free article] [PubMed] [Google Scholar]
36. Rakotomalala R, Rahariniainasoa A, Rakotonindrina Fet al. Intestinal carriage of ESBL-E among sick children in Mahajanga, Madagascar. BMR Microbiol 2019: 1–3. [Google Scholar]
37. Sallem R B, Slama K B, Estepa Vet al. Detection of CTX-M-15-producing Escherichia coli isolates of lineages ST410-A, ST617-A and ST354-D in faecal samples of hospitalized patients in a Mauritanian hospital. J Chemother 2015; 27: 114–6. [DOI] [PubMed] [Google Scholar]
38. Founou RC, Founou LL, Essack SY. Extended spectrum β-lactamase mediated resistance in carriage and clinical gram-negative ESKAPE bacteria: a comparative study between a district and tertiary hospital in South Africa. Antimicrob Resist Infect Control 2018; 7: 134. [DOI] [PMC free article] [PubMed] [Google Scholar]
39. Akinduti PA, Olasehinde GI, Oluwaseun Eet al. Fecal carriage and phylodiversity of community-acquired bla_TEM enteric bacilli in Southwest Nigeria. Infect Drug Resist 2018; 11: 2425–33. [DOI] [PMC free article] [PubMed] [Google Scholar]
40. Herindrainy P, Rabenandrasana MAN, Andrianirina ZZet al. Acquisition of extended spectrum β-lactamase-producing Enterobacteriaceae in neonates: a community based cohort in Madagascar. PLoS One 2018; 13: e0193325. [DOI] [PMC free article] [PubMed] [Google Scholar]
41. Büdel T, Kuenzli E, Clément Met al. Polyclonal gut colonization with extended-spectrum cephalosporin- and/or colistin-resistant Enterobacteriaceae: a normal status for hotel employees on the island of Zanzibar, Tanzania. J Antimicrob Chemother 2019; 74: 2880–90. [DOI] [PubMed] [Google Scholar]
42. Cortés-Cortés G, Lozano-Zarain P, Torres Cet al. Extended-spectrum β-lactamase-producing Escherichia coli isolated from healthy humans in Mexico, including subclone ST131-B2-O25:H4-H30-Rx. J Glob Antimicrob Resist 2017; 9: 130–4. [DOI] [PubMed] [Google Scholar]
43. Salinas L, Loayza F, Cárdenas Pet al. Environmental spread of extended spectrum β-lactamase (ESBL) producing Escherichia coli and ESBL genes among children and domestic animals in Ecuador. Environ Health Perspect 2021; 129: 027007. [DOI] [PMC free article] [PubMed] [Google Scholar]
44. Woerther P-L, Angebault C, Jacquier Het al. Characterization of fecal extended-spectrum-β-lactamase-producing Escherichia coli in a remote community during a long time period. Antimicrob Agents Chemother 2013; 57: 5060–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
45. Islam S, Selvarangan R, Kanwar Net al. Intestinal carriage of third-generation cephalosporin-resistant and extended-spectrum β-lactamase-producing Enterobacteriaceae in healthy US children. J Ped Infect Dis Soc 2018; 7: 234–40. [DOI] [PMC free article] [PubMed] [Google Scholar]
46. Weisenberg SA, Mediavilla JR, Chen Let al. Extended spectrum β-lactamase-producing Enterobacteriaceae in international travelers and non-travelers in New York City. PLoS One 2012; 7: e45141. [DOI] [PMC free article] [PubMed] [Google Scholar]
47. Araque M, Labrador I. Prevalence of fecal carriage of CTX-M-15 β-lactamase-producing Escherichia coli in healthy children from a rural Andean village in Venezuela. Osong Public Health Res Perspect 2018; 9: 9–15. [DOI] [PMC free article] [PubMed] [Google Scholar]
48. Vasques MRG, Bello AR, Lamas CCet al. β-Lactamase producing enterobacteria isolated from surveillance swabs of patients in a cardiac intensive care unit in Rio de Janeiro, Brazil. Braz J Infect Dis 2011; 15: 28–33. [PubMed] [Google Scholar]
49. Harris AD, Kotetishvili M, Shurland Set al. How important is patient-to-patient transmission in extended-spectrum β-lactamase Escherichia coli acquisition. Am J Infect Control 2007; 35: 97–101. [DOI] [PubMed] [Google Scholar]
50. Han JH, Nachamkin I, Zaoutis TEet al. Risk factors for gastrointestinal tract colonization with extended-spectrum β-lactamase (ESBL)–producing Escherichia coli and Klebsiella species in hospitalized patients. Infect Control Hosp Epidemiol 2012; 33: 1242–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
51. Hashemizadeh Z, Kalantar-Neyestanaki D, Mansouri S. Clonal relationships, antimicrobial susceptibilities, and molecular characterization of extended-spectrum β-lactamase-producing Escherichia coli isolates from urinary tract infections and fecal samples in Southeast Iran. Rev Soc Bras Med Trop 2018; 51: 44–51. [DOI] [PubMed] [Google Scholar]
52. Abdul Rahman EM, El-Sherif RH. High rates of intestinal colonization with extended-spectrum lactamase-producing Enterobacteriaceae among healthy individuals. J Investig Med 2011; 59: 1284–6. [DOI] [PubMed] [Google Scholar]
53. Fam NS, Defasque S, Bert Fet al. Faecal carriage of extended-spectrum β-lactamase (ESBL)-producing enterobacteria in liver disease patients from two hospitals in Egypt and France: a comparative epidemiological study. Epidemiol Infect 2015; 143: 1247–55. [DOI] [PMC free article] [PubMed] [Google Scholar]
54. Aghamohammad S, Badmasti F, Shirazi ASet al. Considerable rate of putative virulent phylo-groups in fecal carriage of extended-spectrum β-lactamase producing Escherichia coli. Infect Genet Evol 2019; 73: 184–9. [DOI] [PubMed] [Google Scholar]
55. Hashemizadeh Z, Mohebi S, Kalantar-Neyestanaki Det al. Prevalence of plasmid-mediated quinolone resistance and ESBLs genes in Escherichia coli isolated from urinary tract infections and fecal samples in Southeast Iran. Gene Reports 2019; 17: 100487. [Google Scholar]
56. Moubareck C, Daoud Z, Hakime NIet al. Countrywide spread of community- and hospital-acquired extended-spectrum -lactamase (CTX-M-15)-producing Enterobacteriaceae in Lebanon. J Clin Microbiol 2005; 43: 3309–13. [DOI] [PMC free article] [PubMed] [Google Scholar]
57. Hijazi SM, Fawzi MA, Ali FMet al. Multidrug-resistant ESBL-producing Enterobacteriaceae and associated risk factors in community infants in Lebanon. J Infect Dev Ctries 2016; 10: 947–55. [DOI] [PubMed] [Google Scholar]
58. Daoud Z, Moubareck C, Hakime Net al. Extended spectrum β-lactamase producing Enterobacteriaceae in Lebanese ICU patients: epidemiology and patterns of resistance. J Gen Appl Microbiol 2006; 52: 169–78. [DOI] [PubMed] [Google Scholar]
59. Barguigua A, Ouair H, El Otmani Fet al. Fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae in community setting in Casablanca. Infect Dis (Lond) 2015; 47: 27–32. [DOI] [PubMed] [Google Scholar]
60. Kader AA, Kamath KA. Faecal carriage of extended-spectrum β-lactamase-producing bacteria in the community. East Mediterr Health J 2009; 15: 1365–70. [PubMed] [Google Scholar]
61. Elkersh T, Marie MA, Al-Sheikh YAet al. Prevalence of fecal carriage of extended-spectrum- and metallo-β-lactamase-producing Gram-negative bacteria among neonates born in a hospital setting in central Saudi Arabia. Ann Saudi Med 2015; 35: 240–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
62. Kader AA, Kumar A, Kamath KA. Fecal carriage of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in patients and asymptomatic healthy individuals. Infect Control Hosp Epidemiol 2007; 28: 1114–6. [DOI] [PubMed] [Google Scholar]
63. Ferjani S, Saidani M, Hamzaoui Zet al. Community fecal carriage of broad-spectrum cephalosporin-resistant Escherichia coli in Tunisian children. Diagn Microbiol Infect Dis 2017; 87: 188–92. [DOI] [PubMed] [Google Scholar]
64. Valenza G, Nickel S, Pfeifer Yet al. Extended-spectrum-β-lactamase-producing Escherichia coli as intestinal colonizers in the German community. Antimicrob Agents Chemother 2014; 58: 1228–30. [DOI] [PMC free article] [PubMed] [Google Scholar]
65. Lübbert C, Straube L, Stein Cet al. Colonization with extended-spectrum β-lactamase-producing and carbapenemase-producing Enterobacteriaceae in international travelers returning to Germany. Int J Med Microbiol 2015; 305: 148–56. [DOI] [PubMed] [Google Scholar]
66. Guimarães B, Barreto Â, Radhouani Het al. Genetic detection of extended-spectrum β-lactamase–containing Escherichia coli isolates and vancomycin-resistant enterococci in fecal samples of healthy children. Microb Drug Resist 2009; 15: 211–6. [DOI] [PubMed] [Google Scholar]
67. Latour K, Huang T-D, Jans Bet al. Prevalence of multidrug-resistant organisms in nursing homes in Belgium in 2015. PLoS One 2019; 14: e0214327. [DOI] [PMC free article] [PubMed] [Google Scholar]
68. Ruh E, Zakka J, Hoti Ket al. Extended-spectrum β-lactamase, plasmid-mediated AmpC β-lactamase, fluoroquinolone resistance, and decreased susceptibility to carbapenems in Enterobacteriaceae: fecal carriage rates and associated risk factors in the community of Northern Cyprus. Antimicrob Resist Infect Control 2019; 8: 98. [DOI] [PMC free article] [PubMed] [Google Scholar]
69. Dall LB, Lausch KR, Gedebjerg Aet al. Do probiotics prevent colonization with multi-resistant Enterobacteriaceae during travel? A randomized controlled trial. Travel Med Infect Dis 2019; 27: 81–6. [DOI] [PubMed] [Google Scholar]
70. Bert F, Larroque B, Paugam-Burtz Cet al. Pretransplant fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae and infection after liver transplant, France. Emerging Infect Dis 2012; 18: 908–16. [DOI] [PMC free article] [PubMed] [Google Scholar]
71. Leflon-Guibout V, Blanco J, Amaqdouf Ket al. Absence of CTX-M enzymes but high prevalence of clones, including clone ST131, among fecal Escherichia coli isolates from healthy subjects living in the area of Paris, France. J Clin Microbiol 2008; 46: 3900–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
72. Janvier F, Mérens A, Delaune Det al. Portage digestif d’entérobactéries résistantes aux céphalosporines de troisième génération dans une population d’adultes jeunes asymptomatiques : évolution entre 1999 et 2009. Pathol Biol (Paris) 2011; 59: 97–101. [DOI] [PubMed] [Google Scholar]
73. Pilmis B, Cattoir V, Lecointe Det al. Carriage of ESBL-producing Enterobacteriaceae in French hospitals: the PORTABLSE study. J Hosp Infect 2018; 98: 247–52. [DOI] [PubMed] [Google Scholar]
74. Vidal-Navarro L, Pfeiffer C, Bouziges Net al. Faecal carriage of multidrug-resistant Gram-negative bacilli during a non-outbreak situation in a French university hospital. J Antimicrob Chemother 2010; 65: 2455–8. [DOI] [PubMed] [Google Scholar]
75. Boutet-Dubois A, Pantel A, Prère M-Fet al. Faecal carriage of oxyiminocephalosporin-resistant Enterobacteriaceae among paediatric units in different hospitals in the south of France. Eur J Clin Microbiol Infect Dis 2013; 32: 1063–8. [DOI] [PubMed] [Google Scholar]
76. Le Bastard Q, Chapelet G, Birgand Get al. Gut microbiome signatures of nursing home residents carrying Enterobacteria producing extended-spectrum β-lactamases. Antimicrob Resist Infect Control 2020; 9: 107. [DOI] [PMC free article] [PubMed] [Google Scholar]
77. Jolivet S, Vaillant L, Poncin Tet al. Prevalence of carriage of extended-spectrum β-lactamase-producing enterobacteria and associated factors in a French hospital. Clin Microbiol Infect 2018; 24: 1311–4. [DOI] [PubMed] [Google Scholar]
78. Meyer E, Gastmeier P, Kola Aet al. Pet animals and foreign travel are risk factors for colonisation with extended-spectrum β-lactamase-producing Escherichia coli. Infection 2012; 40: 685–7. [DOI] [PubMed] [Google Scholar]
79. Vehreschild MJGT, Hamprecht A, Peterson Let al. A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies. J Antimicrob Chemother 2014; 69: 3387–92. [DOI] [PubMed] [Google Scholar]
80. Hamprecht A, Rohde AM, Behnke Met al. Colonization with third-generation cephalosporin-resistant Enterobacteriaceae on hospital admission: prevalence and risk factors. J Antimicrob Chemother 2016; 71: 2957–63. [DOI] [PubMed] [Google Scholar]
81. Reinheimer C, Keppler OT, Stephan Cet al. Elevated prevalence of multidrug-resistant gram-negative organisms in HIV positive men. BMC Infect Dis 2017; 17: 206. [DOI] [PMC free article] [PubMed] [Google Scholar]
82. Arvand M, Ruscher C, Bettge-Weller Get al. Prevalence and risk factors for colonization by Clostridium difficile and extended-spectrum β-lactamase-producing Enterobacteriaceae in rehabilitation clinics in Germany. J Hosp Infect 2018; 98: 14–20. [DOI] [PubMed] [Google Scholar]
83. Ebrahimi F, Mózes J, Mészáros Jet al. Asymptomatic faecal carriage of ESBL producing enterobacteriaceae in Hungarian healthy individuals and in long-term care applicants: a shift towards CTX-M producers in the community. Infect Dis (Lond) 2016; 48: 557–9. [DOI] [PubMed] [Google Scholar]
84. Ebrahimi F, Mózes J, Monostori Jet al. Comparison of rates of fecal colonization with extended-spectrum β-lactamase-producing enterobacteria among patients in different wards, outpatients and medical students. Microbiol Immunol 2016; 60: 285–94. [DOI] [PubMed] [Google Scholar]
85. Adler A, Gniadkowski M, Baraniak Aet al. Transmission dynamics of ESBL-producing Escherichia coli clones in rehabilitation wards at a tertiary care centre. Clin Microbiol Infect 2012; 18: E497–505. [DOI] [PubMed] [Google Scholar]
86. Giufrè M, Ricchizzi E, Accogli Met al. Colonization by multidrug-resistant organisms in long-term care facilities in Italy: a point-prevalence study. Clin Microbiol Infect 2017; 23: 961–7. [DOI] [PubMed] [Google Scholar]
87. March A, Aschbacher R, Dhanji Het al. Colonization of residents and staff of a long-term-care facility and adjacent acute-care hospital geriatric unit by multiresistant bacteria. Clin Microbiol Infect 2010; 16: 934–44. [DOI] [PubMed] [Google Scholar]
88. Meletiadis J, Turlej-Rogacka A, Lerner Aet al. Amplification of antimicrobial resistance in gut flora of patients treated with ceftriaxone. Antimicrob Agents Chemother 2017; 61: e00473-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
89. Willemsen I, Nelson J, Hendriks Yet al. Extensive dissemination of extended spectrum β-lactamase-producing Enterobacteriaceae in a Dutch nursing home. Infect Control Hosp Epidemiol 2015; 36: 394–400. [DOI] [PubMed] [Google Scholar]
90. Overdevest I, Haverkate M, Veenemans Jet al. Prolonged colonisation with Escherichia coli O25:ST131 versus other extended-spectrum β-lactamase-producing E. coli in a long-term care facility with high endemic level of rectal colonisation, the Netherlands, 2013 to 2014. Euro Surveill 2016; 21: 30376. [DOI] [PMC free article] [PubMed] [Google Scholar]
91. Kluytmans-van den Bergh MFQ, van Mens SP, Haverkate MRet al. Quantifying hospital-acquired carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae among patients in Dutch hospitals. Infect Control Hosp Epidemiol 2018; 39: 32–9. [DOI] [PubMed] [Google Scholar]
92. Ulstad CR, Solheim M, Berg Set al. Carriage of ESBL/AmpC-producing or ciprofloxacin non-susceptible Escherichia coli and Klebsiella spp. in healthy people in Norway. Antimicrob Resist Infect Control 2016; 5: 57. [DOI] [PMC free article] [PubMed] [Google Scholar]
93. Sadowska-Klasa A, Piekarska A, Prejzner Wet al. Colonization with multidrug-resistant bacteria increases the risk of complications and a fatal outcome after allogeneic hematopoietic cell transplantation. Ann Hematol 2018; 97: 509–17. [DOI] [PMC free article] [PubMed] [Google Scholar]
94. Aires-de-Sousa M, Lopes E, Gonçalves MLet al. Intestinal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae at admission in a Portuguese hospital. Eur J Clin Microbiol Infect Dis 2020; 39: 783–90. [DOI] [PubMed] [Google Scholar]
95. Valverde A, Coque TM, Sanchez-Moreno MPet al. Dramatic increase in prevalence of fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol 2004; 42: 4769–75. [DOI] [PMC free article] [PubMed] [Google Scholar]
96. Jiménez-Rámila C, López-Cerero L, Aguilar Martín MVet al. Vagino-rectal colonization and maternal–neonatal transmission of Enterobacteriaceae producing extended-spectrum β-lactamases or carbapenemases: a cross-sectional study. J Hosp Infect 2019; 101: 167–74. [DOI] [PubMed] [Google Scholar]
97. Paniagua R, Valverde A, Coque TMet al. Assessment of prevalence and changing epidemiology of extended-spectrum β-lactamase-producing Enterobacteriaceae fecal carriers using a chromogenic medium. Diagn Microbiol Infect Dis 2010; 67: 376–9. [DOI] [PubMed] [Google Scholar]
98. Calatayud L, Arnan M, Liñares Jet al. Prospective study of fecal colonization by extended-spectrum-β-lactamase-producing Escherichia coli in neutropenic patients with cancer. Antimicrob Agents Chemother 2008; 52: 4187–90. [DOI] [PMC free article] [PubMed] [Google Scholar]
99. Miró E, Mirelis B, Navarro Fet al. Surveillance of extended-spectrum β-lactamases from clinical samples and faecal carriers in Barcelona, Spain. J Antimicrob Chemother 2005; 56: 1152–5. [DOI] [PubMed] [Google Scholar]
100. Colmenarejo C, Hernández-García M, Muñoz-Rodríguez JRet al. Prevalence and risks factors associated with ESBL-producing faecal carriage in a single long-term-care facility in Spain: emergence of CTX-M-24- and CTX-M-27-producing Escherichia coli ST131-H30R. J Antimicrob Chemother 2020; 75: 2480–4. [DOI] [PubMed] [Google Scholar]
101. Kaarme J, Molin Y, Olsen Bet al. Prevalence of extended-spectrum β-lactamase-producing Enterobacteriaceae in healthy Swedish preschool children. Acta Paediatr 2013; 102: 655–60. [DOI] [PubMed] [Google Scholar]
102. Ny S, Löfmark S, Börjesson Set al. Community carriage of ESBL-producing Escherichia coli is associated with strains of low pathogenicity: a Swedish nationwide study. J Antimicrob Chemother 2017; 72: 582–8. [DOI] [PubMed] [Google Scholar]
103. Strömdahl H, Tham J, Melander Eet al. Prevalence of faecal ESBL carriage in the community and in a hospital setting in a county of Southern Sweden. Eur J Clin Microbiol Infect Dis 2011; 30: 1159–62. [DOI] [PubMed] [Google Scholar]
104. Chabok A, Tärnberg M, Smedh Ket al. Prevalence of fecal carriage of antibiotic-resistant bacteria in patients with acute surgical abdominal infections. Scand J Gastroenterol 2010; 45: 1203–10. [DOI] [PubMed] [Google Scholar]
105. Blom A, Ahl J, Månsson Fet al. The prevalence of ESBL-producing Enterobacteriaceae in a nursing home setting compared with elderly living at home: a cross-sectional comparison. BMC Infect Dis 2016; 16: 111. [DOI] [PMC free article] [PubMed] [Google Scholar]
106. Andersson H, Lindholm C, Iversen Aet al. Prevalence of antibiotic-resistant bacteria in residents of nursing homes in a Swedish municipality: healthcare staff knowledge of and adherence to principles of basic infection prevention. Scand J Infect Dis 2012; 44: 641–9. [DOI] [PubMed] [Google Scholar]
107. Kuenzli E, Jaeger VK, Frei Ret al. High colonization rates of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli in Swiss travellers to South Asia– a prospective observational multicentre cohort study looking at epidemiology, microbiology and risk factors. BMC Infect Dis 2014; 14: 528. [DOI] [PMC free article] [PubMed] [Google Scholar]
108. Tukenmez Tigen E, Tandogdu Z, Ergonul Oet al. Outcomes of fecal carriage of extended-spectrum β-lactamase after transrectal ultrasound–guided biopsy of the prostate. Urology 2014; 84: 1008–15. [DOI] [PubMed] [Google Scholar]
109. Blane B, Brodrick HJ, Gouliouris Tet al. Comparison of 2 chromogenic media for the detection of extended-spectrum β-lactamase producing Enterobacteriaceae stool carriage in nursing home residents. Diagn Microbiol Infect Dis 2016; 84: 181–3. [DOI] [PMC free article] [PubMed] [Google Scholar]
110. Munday CJ, Whitehead GM, Todd NJet al. Predominance and genetic diversity of community- and hospital-acquired CTX-M extended-spectrum β-lactamases in York, UK. J Antimicrob Chemother 2004; 54: 628–33. [DOI] [PubMed] [Google Scholar]
111. Mathai D, Kumar VA, Paul Bet al. Fecal carriage rates of extended-spectrum β-lactamase-producing Escherichia coli among antibiotic naive healthy human volunteers. Microb Drug Resist 2015; 21: 59–64. [DOI] [PubMed] [Google Scholar]
112. Rousham EK, Unicomb L, Islam MA. Human, animal and environmental contributors to antibiotic resistance in low-resource settings: integrating behavioural, epidemiological and One Health approaches. Proc R Soc B 2018; 285:20180332. [DOI] [PMC free article] [PubMed] [Google Scholar]
113. Babu R, Kumar A, Karim Set al. Faecal carriage rate of extended-spectrum β-lactamase-producing Enterobacteriaceae in hospitalised patients and healthy asymptomatic individuals coming for health check-up. J Glob Antimicrob Resist 2016; 6: 150–3. [DOI] [PubMed] [Google Scholar]
114. Maharjan A, Bhetwal A, Shakya Set al. Ugly bugs in healthy guts! Carriage of multidrug-resistant and ESBL-producing commensal Enterobacteriaceae in the intestine of healthy Nepalese adults. Infect Drug Resist 2018; 11: 547–54. [DOI] [PMC free article] [PubMed] [Google Scholar]
115. Luvsansharav U-O, Hirai I, Nakata Aet al. Prevalence of and risk factors associated with faecal carriage of CTX-M -lactamase-producing Enterobacteriaceae in rural Thai communities. J Antimicrob Chemother 2012; 67: 1769–74. [DOI] [PubMed] [Google Scholar]
116. Mulki SS, Ramamurthy K, Bhat S. Fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae in intensive care unit patients. Indian J Crit Care Med 2017; 21: 525–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
117. Severin JA, Lestari ES, Kloezen Wet al. Faecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae among humans in Java, Indonesia, in 2001-2002. Trop Med Int Health 2012; 17: 455–61. [DOI] [PubMed] [Google Scholar]
118. Kiddee A, Assawatheptawee K, Na-Udom Aet al. Risk factors for extended-spectrum β-lactamase-producing Enterobacteriaceae carriage in patients admitted to intensive care unit in a tertiary care hospital in Thailand. Microb Drug Resist 2019; 25: 1182–90. [DOI] [PubMed] [Google Scholar]
119. Tian SF, Chen BY, Chu YZet al. Prevalence of rectal carriage of extended-spectrum β-lactamase-producing Escherichia coli among elderly people in community settings in China. Can J Microbiol 2008; 54: 781–5. [DOI] [PubMed] [Google Scholar]
120. Sadahira T, Wada K, Araki Met al. Impact of selective media for detecting fluoroquinolone-insusceptible/extended-spectrum β-lactamase-producing Escherichia coli before transrectal prostate biopsy. Int J Urol 2017; 24: 842–7. [DOI] [PubMed] [Google Scholar]
121. Nakane K, Kawamura K, Goto Ket al. Long-term colonization by bla_CTX-M -harboring Escherichia coli in healthy Japanese people engaged in food handling. Appl Environ Microbiol 2016; 82: 1818–27. [DOI] [PMC free article] [PubMed] [Google Scholar]
122. Nakayama T, Ueda S, Huong BTMet al. Wide dissemination of extended-spectrum β-lactamase-producing Escherichia coli in community residents in the Indochinese peninsula. Infect Drug Resist 2015; 8: 1–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
123. Kennedy K, Collignon P. Colonisation with Escherichia coli resistant to ‘critically important’ antibiotics: a high risk for international travellers. Eur J Clin Microbiol Infect Dis 2010; 29: 1501–6. [DOI] [PubMed] [Google Scholar]
124. Stuart RL, Kotsanas D, Webb Bet al. Prevalence of antimicrobial-resistant organisms in residential aged care facilities. Med J Aust 2011; 195: 530–3. [DOI] [PubMed] [Google Scholar]
125. Lim CJ, Cheng AC, Kennon Jet al. Prevalence of multidrug-resistant organisms and risk factors for carriage in long-term care facilities: a nested case–control study. J Antimicrob Chemother 2014; 69: 1972–80. [DOI] [PubMed] [Google Scholar]
126. Atterby C, Osbjer K, Tepper Vet al. Carriage of carbapenemase- and extended-spectrum cephalosporinase-producing Escherichia coli and Klebsiella pneumoniae in humans and livestock in rural Cambodia; gender and age differences and detection of bla_OXA-48 in humans. Zoonoses Public Health 2019; 66: 603–17. [DOI] [PMC free article] [PubMed] [Google Scholar]
127. Zhou Y, Wu X, Zhang Jet al. High prevalence of CTX-M β-lactamases in Enterobacteriaceae from healthy individuals in Guangzhou, China. Microb Drug Resist 2015; 21: 398–403. [DOI] [PubMed] [Google Scholar]
128. Qin X, Hu F, Wu Set al. Comparison of adhesin genes and antimicrobial susceptibilities between uropathogenic and intestinal commensal Escherichia coli strains. PLoS One 2013; 8: e61169. [DOI] [PMC free article] [PubMed] [Google Scholar]
129. Li B, Sun J-Y, Liu Q-Zet al. High prevalence of CTX-M β-lactamases in faecal Escherichia coli strains from healthy humans in Fuzhou, China. Scand J Infect Dis 2011; 43: 170–4. [DOI] [PubMed] [Google Scholar]
130. Ni Q, Tian Y, Zhang Let al. Prevalence and quinolone resistance of fecal carriage of extended-spectrum β-lactamase-producing Escherichia coli in 6 communities and 2 physical examination center populations in Shanghai, China. Diagn Microbiol Infect Dis 2016; 86: 428–33. [DOI] [PubMed] [Google Scholar]
131. Xu M, Fan Y, Wang Met al. Characteristics of extended-spectrum β-lactamases-producing Escherichia coli in fecal samples of inpatients of Beijing Tongren Hospital. Jpn J Infect Dis 2017; 70: 290–4. [DOI] [PubMed] [Google Scholar]
132. Wen Z, Wei X, Xiao Yet al. Intervention study of the association of antibiotic utilization measures with control of extended-spectrum β-lactamase (ESBL)-producing bacteria. Microbes Infect 2010; 12: 710–5. [DOI] [PubMed] [Google Scholar]
133. Kamei J, Yagihara Y, Kume Het al. Prevalence and characteristics of fecal antimicrobial-resistant Escherichia coli in a cohort of Japanese men undergoing prostate biopsy. Int J Urol 2017; 24: 295–300. [DOI] [PubMed] [Google Scholar]
134. Higa S, Sarassari R, Hamamoto Ket al. Characterization of CTX-M type ESBL-producing Enterobacteriaceae isolated from asymptomatic healthy individuals who live in a community of the Okinawa prefecture, Japan. J Infect Chemother 2019; 25: 314–7. [DOI] [PubMed] [Google Scholar]
135. Nakamura A, Komatsu M, Noguchi Net al. Analysis of molecular epidemiologic characteristics of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli colonizing feces in hospital patients and community dwellers in a Japanese city. J Infect Chemother 2016; 22: 102–7. [DOI] [PubMed] [Google Scholar]
136. Luvsansharav U-O, Hirai I, Niki Met al. Fecal carriage of CTX-M β-lactamase-producing Enterobacteriaceae in nursing homes in the Kinki region of Japan. Infect Drug Resist 2013; 6: 67–70. [DOI] [PMC free article] [PubMed] [Google Scholar]
137. Takano C, Seki M, Shiihara Het al. Frequent isolation of extended-spectrum β-lactamase-producing bacteria from fecal samples of individuals with severe motor and intellectual disabilities. J Infect Chemother 2018; 24: 182–7. [DOI] [PubMed] [Google Scholar]
138. Kawamura K, Hayashi K, Matsuo Net al. Prevalence of CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli B2-O25-ST131 H30R among residents in nonacute care facilities in Japan. Microb Drug Resist 2018; 24: 1513–20. [DOI] [PubMed] [Google Scholar]
139. Baljin B, Baldan G, Chimeddorj Bet al. Faecal carriage of Gram-negative multidrug-resistant bacteria among patients hospitalized in two centres in Ulaanbaatar, Mongolia. PLoS One 2016; 11: e0168146. [DOI] [PMC free article] [PubMed] [Google Scholar]
140. Mo Y, Seah I, Lye PSPet al. Relating knowledge, attitude and practice of antibiotic use to extended-spectrum β-lactamase-producing Enterobacteriaceae carriage: results of a cross-sectional community survey. BMJ Open 2019; 9: e023859. [DOI] [PMC free article] [PubMed] [Google Scholar]
141. Joo E-J, Kim SJ, Baek Met al. Fecal carriage of antimicrobial-resistant Enterobacteriaceae in healthy Korean adults. J Microbiol Biotechnol 2018; 28: 1178–84. [DOI] [PubMed] [Google Scholar]
142. Wu P-C, Wang J-L, Hsueh P-Ret al. Prevalence and risk factors for colonization by extended-spectrum β-lactamase-producing or ST 131 Escherichia coli among asymptomatic adults in community settings in Southern Taiwan. Infect Drug Resist 2019; 12: 1063–71. [DOI] [PMC free article] [PubMed] [Google Scholar]
143. Huang Y-S, Lai L-C, Chen Y-Aet al. Colonization with multidrug-resistant organisms among healthy adults in the community setting: prevalence, risk factors, and composition of gut microbiome. Front Microbiol 2020; 11: 1402. [DOI] [PMC free article] [PubMed] [Google Scholar]
144. Thi Quynh Nhi L, Thanh Tuyen H, Duc Trung Pet al. Excess body weight and age associated with the carriage of fluoroquinolone and third-generation cephalosporin resistance genes in commensal Escherichia coli from a cohort of urban Vietnamese children. J Med Microbiol 2018; 67: 1457–66. [DOI] [PubMed] [Google Scholar]
145. Thuy DB, Campbell J, Nhat LTHet al. Hospital-acquired colonization and infections in a Vietnamese intensive care unit. PLoS One 2018; 13: e0203600. [DOI] [PMC free article] [PubMed] [Google Scholar]
146. UNSD . Methodology. https://unstats.un.org/unsd/methodology/m49/.

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

dlac048_Supplementary_Data

Click here for additional data file.^{(1.5MB, docx)}

[dlac048-B1] 1. Bezabih YM, Sabiiti W, Alamneh Eet al. The global prevalence and trend of human intestinal carriage of ESBL-producing Escherichia coli in the community. J Antimicrob Chemother 2021; 76: 22–9. [DOI] [PubMed] [Google Scholar]

[dlac048-B2] 2. Melzer M, Petersen I. Mortality following bacteraemic infection caused by extended spectrum β-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J Infect 2007; 55: 254–9. [DOI] [PubMed] [Google Scholar]

[dlac048-B3] 3. Sakran W, Smolkin V, Odetalla Aet al. Community-acquired urinary tract infection in hospitalized children: etiology and antimicrobial resistance. A comparison between first episode and recurrent infection. Clin Pediatr (Phila) 2015; 54: 479–83. [DOI] [PubMed] [Google Scholar]

[dlac048-B4] 4. Chervet D, Lortholary O, Zahar J-Ret al. Antimicrobial resistance in community-acquired urinary tract infections in Paris in 2015. Med Mal Infect 2018; 48: 188–92. [DOI] [PubMed] [Google Scholar]

[dlac048-B5] 5. Ranjan Dash N, Albataineh MT, Alhourani Net al. Community-acquired urinary tract infections due to extended-spectrum β -lactamase-producing organisms in United Arab Emirates. Travel Med Infect Dis 2018; 22: 46–50. [DOI] [PubMed] [Google Scholar]

[dlac048-B6] 6. Al-Mayahie S, Al Kuriashy JJ. Distribution of ESBLs among Escherichia coli isolates from outpatients with recurrent UTIs and their antimicrobial resistance. J Infect Dev Ctries 2016; 10: 575–83. [DOI] [PubMed] [Google Scholar]

[dlac048-B7] 7. Ouchar Mahamat O, Tidjani A, Lounnas Met al. Fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae in hospital and community settings in Chad. Antimicrob Resist Infect Control 2019; 8: 169. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B8] 8. Ko YJ, Moon H-W, Hur Met al. Fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae in Korean community and hospital settings. Infection 2013; 41: 9–13. [DOI] [PubMed] [Google Scholar]

[dlac048-B9] 9. Kurz MSE, Bayingana C, Ndoli JMet al. Intense pre-admission carriage and further acquisition of ESBL-producing Enterobacteriaceae among patients and their caregivers in a tertiary hospital in Rwanda. Trop Med Int Health 2017; 22: 210–20. [DOI] [PubMed] [Google Scholar]

[dlac048-B10] 10. van den Bunt G, van Pelt W, Hidalgo Let al. Prevalence, risk factors and genetic characterisation of extended-spectrum β-lactamase and carbapenemase-producing Enterobacteriaceae (ESBL-E and CPE): a community-based cross-sectional study, the Netherlands, 2014 to 2016. Euro Surveill 2019; 24: 1800594. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B11] 11. Arnan M, Gudiol C, Calatayud Let al. Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. Eur J Clin Microbiol Infect Dis 2011; 30: 355–60. [DOI] [PubMed] [Google Scholar]

[dlac048-B12] 12. Zhang H, Zhou Y, Guo Set al. High prevalence and risk factors of fecal carriage of CTX-M type extended-spectrum β-lactamase-producing Enterobacteriaceae from healthy rural residents of Taian, China. Front Microbiol 2015; 6: 239. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B13] 13. Reuland EA, Al Naiemi N, Kaiser AMet al. Prevalence and risk factors for carriage of ESBL-producing Enterobacteriaceae in Amsterdam. J Antimicrob Chemother 2016; 71: 1076–82. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B14] 14. Kizilates F, Yakupogullari Y, Berk Het al. Risk factors for fecal carriage of extended-spectrum β-lactamase-producing and carbapenem-resistant Escherichia coli and Klebsiella pneumoniae strains among patients at hospital admission. Am J Infect Control 2020; 49: 333–339. [DOI] [PubMed] [Google Scholar]

[dlac048-B15] 15. Karanika S, Karantanos T, Arvanitis Met al. Fecal colonization with extended-spectrum β-lactamase–producing Enterobacteriaceae and risk factors among healthy individuals: a systematic review and metaanalysis. Clin Infect Dis 2016; 63: 310–8. [DOI] [PubMed] [Google Scholar]

[dlac048-B16] 16. PRISMA . http://prisma-statement.org/prismastatement/Checklist.aspx.

[dlac048-B17] 17. Jørgensen SB, Søraas A, Sundsfjord Aet al. Fecal carriage of extended spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae after urinary tract infection – a three year prospective cohort study. PLoS One 2017; 12: e0173510. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B18] 18. Rodríguez-Baño J, Alcalá JC, Cisneros JMet al. Community infections caused by extended-spectrum β-lactamase–producing Escherichia coli. Arch Intern Med 2008; 168: 1897–902. [DOI] [PubMed] [Google Scholar]

[dlac048-B19] 19. National Heart, Lung, and Blood Institute (NHLBI) . Study Quality Assessment Tools. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools.

[dlac048-B20] 20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–88. [DOI] [PubMed] [Google Scholar]

[dlac048-B21] 21. WHO Definition of Region Groupings . 2013. https://www.who.int/about/who-we-are/regional-offices.

[dlac048-B22] 22. Fazel S, Khosla V, Doll Het al. The prevalence of mental disorders among the homeless in Western countries: systematic review and meta-regression analysis. PLoS Med 2008; 5: e225. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B23] 23. Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health 2014; 72: 39. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B24] 24. Egger M, Davey Smith G, Schneider Met al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–34. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B25] 25. Wallace BC, Lajeunesse MJ, Dietz Get al. Open MEE: intuitive, open-source software for meta-analysis in ecology and evolutionary biology. Methods Ecol Evol 2017; 8: 941–7. [Google Scholar]

[dlac048-B26] 26. Tschudin-Sutter S, Lucet J-C, Mutters NTet al. Contact precautions for preventing nosocomial transmission of extended-spectrum β lactamase–producing Escherichia coli: a point/counterpoint review. Clin Infect Dis 2017; 65: 342–7. [DOI] [PubMed] [Google Scholar]

[dlac048-B27] 27. Maechler F, Schwab F, Hansen Set al. Contact isolation versus standard precautions to decrease acquisition of extended-spectrum β-lactamase-producing Enterobacterales in non-critical care wards: a cluster-randomised crossover trial. Lancet Infect Dis 2020; 20: 575–84. [DOI] [PubMed] [Google Scholar]

[dlac048-B28] 28. Mshana SE, Falgenhauer L, Mirambo MMet al. Predictors of bla_CTX-M-15 in varieties of Escherichia coli genotypes from humans in community settings in Mwanza, Tanzania. BMC Infect Dis 2016; 16: 187. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B29] 29. Medboua-Benbalagh C, Touati A, Kermas Ret al. Fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae strains is associated with worse outcome in patients hospitalized in the pediatric oncology unit of Beni-Messous Hospital in Algiers, Algeria. Microb Drug Resist 2017; 23: 757–63. [DOI] [PubMed] [Google Scholar]

[dlac048-B30] 30. Ouédraogo A-S, Sanou S, Kissou Aet al. Fecal carriage of Enterobacteriaceae producing extended-spectrum β-lactamases in hospitalized patients and healthy community volunteers in Burkina Faso. Microb Drug Resist 2017; 23: 63–70. [DOI] [PubMed] [Google Scholar]

[dlac048-B31] 31. Lonchel CM, Melin P, Gangoué-Piéboji Jet al. Extended-spectrum β-lactamase-producing Enterobacteriaceae in Cameroonian hospitals. Eur J Clin Microbiol Infect Dis 2013; 32: 79–87. [DOI] [PubMed] [Google Scholar]

[dlac048-B32] 32. Aklilu A, Manilal A, Ameya Get al. Gastrointestinal tract colonization rate of extended-spectrum β-lactamase- and carbapenemase-producing Enterobacteriaceae and associated factors among hospitalized patients in Arba Minch General Hospital, Arba Minch, Ethiopia. Infect Drug Resist 2020; 13: 1517–26. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B33] 33. Desta K, Woldeamanuel Y, Azazh Aet al. High gastrointestinal colonization rate with extended-spectrum β-lactamase-producing Enterobacteriaceae in hospitalized patients: emergence of carbapenemase-producing K. pneumoniae in Ethiopia. PLoS One 2016; 11: e0161685. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B34] 34. Falgenhauer L, Imirzalioglu C, Oppong Ket al. Detection and characterization of ESBL-producing Escherichia coli from humans and poultry in Ghana. Front Microbiol 2019; 9: 3358. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B35] 35. Isendahl J, Turlej-Rogacka A, Manjuba Cet al. Fecal carriage of ESBL-producing E. coli and K. pneumoniae in children in Guinea-Bissau: a hospital-based cross-sectional study. PLoS One 2012; 7: e51981. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B36] 36. Rakotomalala R, Rahariniainasoa A, Rakotonindrina Fet al. Intestinal carriage of ESBL-E among sick children in Mahajanga, Madagascar. BMR Microbiol 2019: 1–3. [Google Scholar]

[dlac048-B37] 37. Sallem R B, Slama K B, Estepa Vet al. Detection of CTX-M-15-producing Escherichia coli isolates of lineages ST410-A, ST617-A and ST354-D in faecal samples of hospitalized patients in a Mauritanian hospital. J Chemother 2015; 27: 114–6. [DOI] [PubMed] [Google Scholar]

[dlac048-B38] 38. Founou RC, Founou LL, Essack SY. Extended spectrum β-lactamase mediated resistance in carriage and clinical gram-negative ESKAPE bacteria: a comparative study between a district and tertiary hospital in South Africa. Antimicrob Resist Infect Control 2018; 7: 134. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B39] 39. Akinduti PA, Olasehinde GI, Oluwaseun Eet al. Fecal carriage and phylodiversity of community-acquired bla_TEM enteric bacilli in Southwest Nigeria. Infect Drug Resist 2018; 11: 2425–33. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B40] 40. Herindrainy P, Rabenandrasana MAN, Andrianirina ZZet al. Acquisition of extended spectrum β-lactamase-producing Enterobacteriaceae in neonates: a community based cohort in Madagascar. PLoS One 2018; 13: e0193325. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B41] 41. Büdel T, Kuenzli E, Clément Met al. Polyclonal gut colonization with extended-spectrum cephalosporin- and/or colistin-resistant Enterobacteriaceae: a normal status for hotel employees on the island of Zanzibar, Tanzania. J Antimicrob Chemother 2019; 74: 2880–90. [DOI] [PubMed] [Google Scholar]

[dlac048-B42] 42. Cortés-Cortés G, Lozano-Zarain P, Torres Cet al. Extended-spectrum β-lactamase-producing Escherichia coli isolated from healthy humans in Mexico, including subclone ST131-B2-O25:H4-H30-Rx. J Glob Antimicrob Resist 2017; 9: 130–4. [DOI] [PubMed] [Google Scholar]

[dlac048-B43] 43. Salinas L, Loayza F, Cárdenas Pet al. Environmental spread of extended spectrum β-lactamase (ESBL) producing Escherichia coli and ESBL genes among children and domestic animals in Ecuador. Environ Health Perspect 2021; 129: 027007. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B44] 44. Woerther P-L, Angebault C, Jacquier Het al. Characterization of fecal extended-spectrum-β-lactamase-producing Escherichia coli in a remote community during a long time period. Antimicrob Agents Chemother 2013; 57: 5060–6. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B45] 45. Islam S, Selvarangan R, Kanwar Net al. Intestinal carriage of third-generation cephalosporin-resistant and extended-spectrum β-lactamase-producing Enterobacteriaceae in healthy US children. J Ped Infect Dis Soc 2018; 7: 234–40. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B46] 46. Weisenberg SA, Mediavilla JR, Chen Let al. Extended spectrum β-lactamase-producing Enterobacteriaceae in international travelers and non-travelers in New York City. PLoS One 2012; 7: e45141. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B47] 47. Araque M, Labrador I. Prevalence of fecal carriage of CTX-M-15 β-lactamase-producing Escherichia coli in healthy children from a rural Andean village in Venezuela. Osong Public Health Res Perspect 2018; 9: 9–15. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B48] 48. Vasques MRG, Bello AR, Lamas CCet al. β-Lactamase producing enterobacteria isolated from surveillance swabs of patients in a cardiac intensive care unit in Rio de Janeiro, Brazil. Braz J Infect Dis 2011; 15: 28–33. [PubMed] [Google Scholar]

[dlac048-B49] 49. Harris AD, Kotetishvili M, Shurland Set al. How important is patient-to-patient transmission in extended-spectrum β-lactamase Escherichia coli acquisition. Am J Infect Control 2007; 35: 97–101. [DOI] [PubMed] [Google Scholar]

[dlac048-B50] 50. Han JH, Nachamkin I, Zaoutis TEet al. Risk factors for gastrointestinal tract colonization with extended-spectrum β-lactamase (ESBL)–producing Escherichia coli and Klebsiella species in hospitalized patients. Infect Control Hosp Epidemiol 2012; 33: 1242–5. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B51] 51. Hashemizadeh Z, Kalantar-Neyestanaki D, Mansouri S. Clonal relationships, antimicrobial susceptibilities, and molecular characterization of extended-spectrum β-lactamase-producing Escherichia coli isolates from urinary tract infections and fecal samples in Southeast Iran. Rev Soc Bras Med Trop 2018; 51: 44–51. [DOI] [PubMed] [Google Scholar]

[dlac048-B52] 52. Abdul Rahman EM, El-Sherif RH. High rates of intestinal colonization with extended-spectrum lactamase-producing Enterobacteriaceae among healthy individuals. J Investig Med 2011; 59: 1284–6. [DOI] [PubMed] [Google Scholar]

[dlac048-B53] 53. Fam NS, Defasque S, Bert Fet al. Faecal carriage of extended-spectrum β-lactamase (ESBL)-producing enterobacteria in liver disease patients from two hospitals in Egypt and France: a comparative epidemiological study. Epidemiol Infect 2015; 143: 1247–55. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B54] 54. Aghamohammad S, Badmasti F, Shirazi ASet al. Considerable rate of putative virulent phylo-groups in fecal carriage of extended-spectrum β-lactamase producing Escherichia coli. Infect Genet Evol 2019; 73: 184–9. [DOI] [PubMed] [Google Scholar]

[dlac048-B55] 55. Hashemizadeh Z, Mohebi S, Kalantar-Neyestanaki Det al. Prevalence of plasmid-mediated quinolone resistance and ESBLs genes in Escherichia coli isolated from urinary tract infections and fecal samples in Southeast Iran. Gene Reports 2019; 17: 100487. [Google Scholar]

[dlac048-B56] 56. Moubareck C, Daoud Z, Hakime NIet al. Countrywide spread of community- and hospital-acquired extended-spectrum -lactamase (CTX-M-15)-producing Enterobacteriaceae in Lebanon. J Clin Microbiol 2005; 43: 3309–13. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B57] 57. Hijazi SM, Fawzi MA, Ali FMet al. Multidrug-resistant ESBL-producing Enterobacteriaceae and associated risk factors in community infants in Lebanon. J Infect Dev Ctries 2016; 10: 947–55. [DOI] [PubMed] [Google Scholar]

[dlac048-B58] 58. Daoud Z, Moubareck C, Hakime Net al. Extended spectrum β-lactamase producing Enterobacteriaceae in Lebanese ICU patients: epidemiology and patterns of resistance. J Gen Appl Microbiol 2006; 52: 169–78. [DOI] [PubMed] [Google Scholar]

[dlac048-B59] 59. Barguigua A, Ouair H, El Otmani Fet al. Fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae in community setting in Casablanca. Infect Dis (Lond) 2015; 47: 27–32. [DOI] [PubMed] [Google Scholar]

[dlac048-B60] 60. Kader AA, Kamath KA. Faecal carriage of extended-spectrum β-lactamase-producing bacteria in the community. East Mediterr Health J 2009; 15: 1365–70. [PubMed] [Google Scholar]

[dlac048-B61] 61. Elkersh T, Marie MA, Al-Sheikh YAet al. Prevalence of fecal carriage of extended-spectrum- and metallo-β-lactamase-producing Gram-negative bacteria among neonates born in a hospital setting in central Saudi Arabia. Ann Saudi Med 2015; 35: 240–7. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B62] 62. Kader AA, Kumar A, Kamath KA. Fecal carriage of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in patients and asymptomatic healthy individuals. Infect Control Hosp Epidemiol 2007; 28: 1114–6. [DOI] [PubMed] [Google Scholar]

[dlac048-B63] 63. Ferjani S, Saidani M, Hamzaoui Zet al. Community fecal carriage of broad-spectrum cephalosporin-resistant Escherichia coli in Tunisian children. Diagn Microbiol Infect Dis 2017; 87: 188–92. [DOI] [PubMed] [Google Scholar]

[dlac048-B64] 64. Valenza G, Nickel S, Pfeifer Yet al. Extended-spectrum-β-lactamase-producing Escherichia coli as intestinal colonizers in the German community. Antimicrob Agents Chemother 2014; 58: 1228–30. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B65] 65. Lübbert C, Straube L, Stein Cet al. Colonization with extended-spectrum β-lactamase-producing and carbapenemase-producing Enterobacteriaceae in international travelers returning to Germany. Int J Med Microbiol 2015; 305: 148–56. [DOI] [PubMed] [Google Scholar]

[dlac048-B66] 66. Guimarães B, Barreto Â, Radhouani Het al. Genetic detection of extended-spectrum β-lactamase–containing Escherichia coli isolates and vancomycin-resistant enterococci in fecal samples of healthy children. Microb Drug Resist 2009; 15: 211–6. [DOI] [PubMed] [Google Scholar]

[dlac048-B67] 67. Latour K, Huang T-D, Jans Bet al. Prevalence of multidrug-resistant organisms in nursing homes in Belgium in 2015. PLoS One 2019; 14: e0214327. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B68] 68. Ruh E, Zakka J, Hoti Ket al. Extended-spectrum β-lactamase, plasmid-mediated AmpC β-lactamase, fluoroquinolone resistance, and decreased susceptibility to carbapenems in Enterobacteriaceae: fecal carriage rates and associated risk factors in the community of Northern Cyprus. Antimicrob Resist Infect Control 2019; 8: 98. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B69] 69. Dall LB, Lausch KR, Gedebjerg Aet al. Do probiotics prevent colonization with multi-resistant Enterobacteriaceae during travel? A randomized controlled trial. Travel Med Infect Dis 2019; 27: 81–6. [DOI] [PubMed] [Google Scholar]

[dlac048-B70] 70. Bert F, Larroque B, Paugam-Burtz Cet al. Pretransplant fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae and infection after liver transplant, France. Emerging Infect Dis 2012; 18: 908–16. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B71] 71. Leflon-Guibout V, Blanco J, Amaqdouf Ket al. Absence of CTX-M enzymes but high prevalence of clones, including clone ST131, among fecal Escherichia coli isolates from healthy subjects living in the area of Paris, France. J Clin Microbiol 2008; 46: 3900–5. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B72] 72. Janvier F, Mérens A, Delaune Det al. Portage digestif d’entérobactéries résistantes aux céphalosporines de troisième génération dans une population d’adultes jeunes asymptomatiques : évolution entre 1999 et 2009. Pathol Biol (Paris) 2011; 59: 97–101. [DOI] [PubMed] [Google Scholar]

[dlac048-B73] 73. Pilmis B, Cattoir V, Lecointe Det al. Carriage of ESBL-producing Enterobacteriaceae in French hospitals: the PORTABLSE study. J Hosp Infect 2018; 98: 247–52. [DOI] [PubMed] [Google Scholar]

[dlac048-B74] 74. Vidal-Navarro L, Pfeiffer C, Bouziges Net al. Faecal carriage of multidrug-resistant Gram-negative bacilli during a non-outbreak situation in a French university hospital. J Antimicrob Chemother 2010; 65: 2455–8. [DOI] [PubMed] [Google Scholar]

[dlac048-B75] 75. Boutet-Dubois A, Pantel A, Prère M-Fet al. Faecal carriage of oxyiminocephalosporin-resistant Enterobacteriaceae among paediatric units in different hospitals in the south of France. Eur J Clin Microbiol Infect Dis 2013; 32: 1063–8. [DOI] [PubMed] [Google Scholar]

[dlac048-B76] 76. Le Bastard Q, Chapelet G, Birgand Get al. Gut microbiome signatures of nursing home residents carrying Enterobacteria producing extended-spectrum β-lactamases. Antimicrob Resist Infect Control 2020; 9: 107. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B77] 77. Jolivet S, Vaillant L, Poncin Tet al. Prevalence of carriage of extended-spectrum β-lactamase-producing enterobacteria and associated factors in a French hospital. Clin Microbiol Infect 2018; 24: 1311–4. [DOI] [PubMed] [Google Scholar]

[dlac048-B78] 78. Meyer E, Gastmeier P, Kola Aet al. Pet animals and foreign travel are risk factors for colonisation with extended-spectrum β-lactamase-producing Escherichia coli. Infection 2012; 40: 685–7. [DOI] [PubMed] [Google Scholar]

[dlac048-B79] 79. Vehreschild MJGT, Hamprecht A, Peterson Let al. A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies. J Antimicrob Chemother 2014; 69: 3387–92. [DOI] [PubMed] [Google Scholar]

[dlac048-B80] 80. Hamprecht A, Rohde AM, Behnke Met al. Colonization with third-generation cephalosporin-resistant Enterobacteriaceae on hospital admission: prevalence and risk factors. J Antimicrob Chemother 2016; 71: 2957–63. [DOI] [PubMed] [Google Scholar]

[dlac048-B81] 81. Reinheimer C, Keppler OT, Stephan Cet al. Elevated prevalence of multidrug-resistant gram-negative organisms in HIV positive men. BMC Infect Dis 2017; 17: 206. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B82] 82. Arvand M, Ruscher C, Bettge-Weller Get al. Prevalence and risk factors for colonization by Clostridium difficile and extended-spectrum β-lactamase-producing Enterobacteriaceae in rehabilitation clinics in Germany. J Hosp Infect 2018; 98: 14–20. [DOI] [PubMed] [Google Scholar]

[dlac048-B83] 83. Ebrahimi F, Mózes J, Mészáros Jet al. Asymptomatic faecal carriage of ESBL producing enterobacteriaceae in Hungarian healthy individuals and in long-term care applicants: a shift towards CTX-M producers in the community. Infect Dis (Lond) 2016; 48: 557–9. [DOI] [PubMed] [Google Scholar]

[dlac048-B84] 84. Ebrahimi F, Mózes J, Monostori Jet al. Comparison of rates of fecal colonization with extended-spectrum β-lactamase-producing enterobacteria among patients in different wards, outpatients and medical students. Microbiol Immunol 2016; 60: 285–94. [DOI] [PubMed] [Google Scholar]

[dlac048-B85] 85. Adler A, Gniadkowski M, Baraniak Aet al. Transmission dynamics of ESBL-producing Escherichia coli clones in rehabilitation wards at a tertiary care centre. Clin Microbiol Infect 2012; 18: E497–505. [DOI] [PubMed] [Google Scholar]

[dlac048-B86] 86. Giufrè M, Ricchizzi E, Accogli Met al. Colonization by multidrug-resistant organisms in long-term care facilities in Italy: a point-prevalence study. Clin Microbiol Infect 2017; 23: 961–7. [DOI] [PubMed] [Google Scholar]

[dlac048-B87] 87. March A, Aschbacher R, Dhanji Het al. Colonization of residents and staff of a long-term-care facility and adjacent acute-care hospital geriatric unit by multiresistant bacteria. Clin Microbiol Infect 2010; 16: 934–44. [DOI] [PubMed] [Google Scholar]

[dlac048-B88] 88. Meletiadis J, Turlej-Rogacka A, Lerner Aet al. Amplification of antimicrobial resistance in gut flora of patients treated with ceftriaxone. Antimicrob Agents Chemother 2017; 61: e00473-17. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B89] 89. Willemsen I, Nelson J, Hendriks Yet al. Extensive dissemination of extended spectrum β-lactamase-producing Enterobacteriaceae in a Dutch nursing home. Infect Control Hosp Epidemiol 2015; 36: 394–400. [DOI] [PubMed] [Google Scholar]

[dlac048-B90] 90. Overdevest I, Haverkate M, Veenemans Jet al. Prolonged colonisation with Escherichia coli O25:ST131 versus other extended-spectrum β-lactamase-producing E. coli in a long-term care facility with high endemic level of rectal colonisation, the Netherlands, 2013 to 2014. Euro Surveill 2016; 21: 30376. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B91] 91. Kluytmans-van den Bergh MFQ, van Mens SP, Haverkate MRet al. Quantifying hospital-acquired carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae among patients in Dutch hospitals. Infect Control Hosp Epidemiol 2018; 39: 32–9. [DOI] [PubMed] [Google Scholar]

[dlac048-B92] 92. Ulstad CR, Solheim M, Berg Set al. Carriage of ESBL/AmpC-producing or ciprofloxacin non-susceptible Escherichia coli and Klebsiella spp. in healthy people in Norway. Antimicrob Resist Infect Control 2016; 5: 57. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B93] 93. Sadowska-Klasa A, Piekarska A, Prejzner Wet al. Colonization with multidrug-resistant bacteria increases the risk of complications and a fatal outcome after allogeneic hematopoietic cell transplantation. Ann Hematol 2018; 97: 509–17. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B94] 94. Aires-de-Sousa M, Lopes E, Gonçalves MLet al. Intestinal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae at admission in a Portuguese hospital. Eur J Clin Microbiol Infect Dis 2020; 39: 783–90. [DOI] [PubMed] [Google Scholar]

[dlac048-B95] 95. Valverde A, Coque TM, Sanchez-Moreno MPet al. Dramatic increase in prevalence of fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol 2004; 42: 4769–75. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B96] 96. Jiménez-Rámila C, López-Cerero L, Aguilar Martín MVet al. Vagino-rectal colonization and maternal–neonatal transmission of Enterobacteriaceae producing extended-spectrum β-lactamases or carbapenemases: a cross-sectional study. J Hosp Infect 2019; 101: 167–74. [DOI] [PubMed] [Google Scholar]

[dlac048-B97] 97. Paniagua R, Valverde A, Coque TMet al. Assessment of prevalence and changing epidemiology of extended-spectrum β-lactamase-producing Enterobacteriaceae fecal carriers using a chromogenic medium. Diagn Microbiol Infect Dis 2010; 67: 376–9. [DOI] [PubMed] [Google Scholar]

[dlac048-B98] 98. Calatayud L, Arnan M, Liñares Jet al. Prospective study of fecal colonization by extended-spectrum-β-lactamase-producing Escherichia coli in neutropenic patients with cancer. Antimicrob Agents Chemother 2008; 52: 4187–90. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B99] 99. Miró E, Mirelis B, Navarro Fet al. Surveillance of extended-spectrum β-lactamases from clinical samples and faecal carriers in Barcelona, Spain. J Antimicrob Chemother 2005; 56: 1152–5. [DOI] [PubMed] [Google Scholar]

[dlac048-B100] 100. Colmenarejo C, Hernández-García M, Muñoz-Rodríguez JRet al. Prevalence and risks factors associated with ESBL-producing faecal carriage in a single long-term-care facility in Spain: emergence of CTX-M-24- and CTX-M-27-producing Escherichia coli ST131-H30R. J Antimicrob Chemother 2020; 75: 2480–4. [DOI] [PubMed] [Google Scholar]

[dlac048-B101] 101. Kaarme J, Molin Y, Olsen Bet al. Prevalence of extended-spectrum β-lactamase-producing Enterobacteriaceae in healthy Swedish preschool children. Acta Paediatr 2013; 102: 655–60. [DOI] [PubMed] [Google Scholar]

[dlac048-B102] 102. Ny S, Löfmark S, Börjesson Set al. Community carriage of ESBL-producing Escherichia coli is associated with strains of low pathogenicity: a Swedish nationwide study. J Antimicrob Chemother 2017; 72: 582–8. [DOI] [PubMed] [Google Scholar]

[dlac048-B103] 103. Strömdahl H, Tham J, Melander Eet al. Prevalence of faecal ESBL carriage in the community and in a hospital setting in a county of Southern Sweden. Eur J Clin Microbiol Infect Dis 2011; 30: 1159–62. [DOI] [PubMed] [Google Scholar]

[dlac048-B104] 104. Chabok A, Tärnberg M, Smedh Ket al. Prevalence of fecal carriage of antibiotic-resistant bacteria in patients with acute surgical abdominal infections. Scand J Gastroenterol 2010; 45: 1203–10. [DOI] [PubMed] [Google Scholar]

[dlac048-B105] 105. Blom A, Ahl J, Månsson Fet al. The prevalence of ESBL-producing Enterobacteriaceae in a nursing home setting compared with elderly living at home: a cross-sectional comparison. BMC Infect Dis 2016; 16: 111. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B106] 106. Andersson H, Lindholm C, Iversen Aet al. Prevalence of antibiotic-resistant bacteria in residents of nursing homes in a Swedish municipality: healthcare staff knowledge of and adherence to principles of basic infection prevention. Scand J Infect Dis 2012; 44: 641–9. [DOI] [PubMed] [Google Scholar]

[dlac048-B107] 107. Kuenzli E, Jaeger VK, Frei Ret al. High colonization rates of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli in Swiss travellers to South Asia– a prospective observational multicentre cohort study looking at epidemiology, microbiology and risk factors. BMC Infect Dis 2014; 14: 528. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B108] 108. Tukenmez Tigen E, Tandogdu Z, Ergonul Oet al. Outcomes of fecal carriage of extended-spectrum β-lactamase after transrectal ultrasound–guided biopsy of the prostate. Urology 2014; 84: 1008–15. [DOI] [PubMed] [Google Scholar]

[dlac048-B109] 109. Blane B, Brodrick HJ, Gouliouris Tet al. Comparison of 2 chromogenic media for the detection of extended-spectrum β-lactamase producing Enterobacteriaceae stool carriage in nursing home residents. Diagn Microbiol Infect Dis 2016; 84: 181–3. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B110] 110. Munday CJ, Whitehead GM, Todd NJet al. Predominance and genetic diversity of community- and hospital-acquired CTX-M extended-spectrum β-lactamases in York, UK. J Antimicrob Chemother 2004; 54: 628–33. [DOI] [PubMed] [Google Scholar]

[dlac048-B111] 111. Mathai D, Kumar VA, Paul Bet al. Fecal carriage rates of extended-spectrum β-lactamase-producing Escherichia coli among antibiotic naive healthy human volunteers. Microb Drug Resist 2015; 21: 59–64. [DOI] [PubMed] [Google Scholar]

[dlac048-B112] 112. Rousham EK, Unicomb L, Islam MA. Human, animal and environmental contributors to antibiotic resistance in low-resource settings: integrating behavioural, epidemiological and One Health approaches. Proc R Soc B 2018; 285:20180332. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B113] 113. Babu R, Kumar A, Karim Set al. Faecal carriage rate of extended-spectrum β-lactamase-producing Enterobacteriaceae in hospitalised patients and healthy asymptomatic individuals coming for health check-up. J Glob Antimicrob Resist 2016; 6: 150–3. [DOI] [PubMed] [Google Scholar]

[dlac048-B114] 114. Maharjan A, Bhetwal A, Shakya Set al. Ugly bugs in healthy guts! Carriage of multidrug-resistant and ESBL-producing commensal Enterobacteriaceae in the intestine of healthy Nepalese adults. Infect Drug Resist 2018; 11: 547–54. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B115] 115. Luvsansharav U-O, Hirai I, Nakata Aet al. Prevalence of and risk factors associated with faecal carriage of CTX-M -lactamase-producing Enterobacteriaceae in rural Thai communities. J Antimicrob Chemother 2012; 67: 1769–74. [DOI] [PubMed] [Google Scholar]

[dlac048-B116] 116. Mulki SS, Ramamurthy K, Bhat S. Fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae in intensive care unit patients. Indian J Crit Care Med 2017; 21: 525–7. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B117] 117. Severin JA, Lestari ES, Kloezen Wet al. Faecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae among humans in Java, Indonesia, in 2001-2002. Trop Med Int Health 2012; 17: 455–61. [DOI] [PubMed] [Google Scholar]

[dlac048-B118] 118. Kiddee A, Assawatheptawee K, Na-Udom Aet al. Risk factors for extended-spectrum β-lactamase-producing Enterobacteriaceae carriage in patients admitted to intensive care unit in a tertiary care hospital in Thailand. Microb Drug Resist 2019; 25: 1182–90. [DOI] [PubMed] [Google Scholar]

[dlac048-B119] 119. Tian SF, Chen BY, Chu YZet al. Prevalence of rectal carriage of extended-spectrum β-lactamase-producing Escherichia coli among elderly people in community settings in China. Can J Microbiol 2008; 54: 781–5. [DOI] [PubMed] [Google Scholar]

[dlac048-B120] 120. Sadahira T, Wada K, Araki Met al. Impact of selective media for detecting fluoroquinolone-insusceptible/extended-spectrum β-lactamase-producing Escherichia coli before transrectal prostate biopsy. Int J Urol 2017; 24: 842–7. [DOI] [PubMed] [Google Scholar]

[dlac048-B121] 121. Nakane K, Kawamura K, Goto Ket al. Long-term colonization by bla_CTX-M -harboring Escherichia coli in healthy Japanese people engaged in food handling. Appl Environ Microbiol 2016; 82: 1818–27. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B122] 122. Nakayama T, Ueda S, Huong BTMet al. Wide dissemination of extended-spectrum β-lactamase-producing Escherichia coli in community residents in the Indochinese peninsula. Infect Drug Resist 2015; 8: 1–5. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B123] 123. Kennedy K, Collignon P. Colonisation with Escherichia coli resistant to ‘critically important’ antibiotics: a high risk for international travellers. Eur J Clin Microbiol Infect Dis 2010; 29: 1501–6. [DOI] [PubMed] [Google Scholar]

[dlac048-B124] 124. Stuart RL, Kotsanas D, Webb Bet al. Prevalence of antimicrobial-resistant organisms in residential aged care facilities. Med J Aust 2011; 195: 530–3. [DOI] [PubMed] [Google Scholar]

[dlac048-B125] 125. Lim CJ, Cheng AC, Kennon Jet al. Prevalence of multidrug-resistant organisms and risk factors for carriage in long-term care facilities: a nested case–control study. J Antimicrob Chemother 2014; 69: 1972–80. [DOI] [PubMed] [Google Scholar]

[dlac048-B126] 126. Atterby C, Osbjer K, Tepper Vet al. Carriage of carbapenemase- and extended-spectrum cephalosporinase-producing Escherichia coli and Klebsiella pneumoniae in humans and livestock in rural Cambodia; gender and age differences and detection of bla_OXA-48 in humans. Zoonoses Public Health 2019; 66: 603–17. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B127] 127. Zhou Y, Wu X, Zhang Jet al. High prevalence of CTX-M β-lactamases in Enterobacteriaceae from healthy individuals in Guangzhou, China. Microb Drug Resist 2015; 21: 398–403. [DOI] [PubMed] [Google Scholar]

[dlac048-B128] 128. Qin X, Hu F, Wu Set al. Comparison of adhesin genes and antimicrobial susceptibilities between uropathogenic and intestinal commensal Escherichia coli strains. PLoS One 2013; 8: e61169. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B129] 129. Li B, Sun J-Y, Liu Q-Zet al. High prevalence of CTX-M β-lactamases in faecal Escherichia coli strains from healthy humans in Fuzhou, China. Scand J Infect Dis 2011; 43: 170–4. [DOI] [PubMed] [Google Scholar]

[dlac048-B130] 130. Ni Q, Tian Y, Zhang Let al. Prevalence and quinolone resistance of fecal carriage of extended-spectrum β-lactamase-producing Escherichia coli in 6 communities and 2 physical examination center populations in Shanghai, China. Diagn Microbiol Infect Dis 2016; 86: 428–33. [DOI] [PubMed] [Google Scholar]

[dlac048-B131] 131. Xu M, Fan Y, Wang Met al. Characteristics of extended-spectrum β-lactamases-producing Escherichia coli in fecal samples of inpatients of Beijing Tongren Hospital. Jpn J Infect Dis 2017; 70: 290–4. [DOI] [PubMed] [Google Scholar]

[dlac048-B132] 132. Wen Z, Wei X, Xiao Yet al. Intervention study of the association of antibiotic utilization measures with control of extended-spectrum β-lactamase (ESBL)-producing bacteria. Microbes Infect 2010; 12: 710–5. [DOI] [PubMed] [Google Scholar]

[dlac048-B133] 133. Kamei J, Yagihara Y, Kume Het al. Prevalence and characteristics of fecal antimicrobial-resistant Escherichia coli in a cohort of Japanese men undergoing prostate biopsy. Int J Urol 2017; 24: 295–300. [DOI] [PubMed] [Google Scholar]

[dlac048-B134] 134. Higa S, Sarassari R, Hamamoto Ket al. Characterization of CTX-M type ESBL-producing Enterobacteriaceae isolated from asymptomatic healthy individuals who live in a community of the Okinawa prefecture, Japan. J Infect Chemother 2019; 25: 314–7. [DOI] [PubMed] [Google Scholar]

[dlac048-B135] 135. Nakamura A, Komatsu M, Noguchi Net al. Analysis of molecular epidemiologic characteristics of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli colonizing feces in hospital patients and community dwellers in a Japanese city. J Infect Chemother 2016; 22: 102–7. [DOI] [PubMed] [Google Scholar]

[dlac048-B136] 136. Luvsansharav U-O, Hirai I, Niki Met al. Fecal carriage of CTX-M β-lactamase-producing Enterobacteriaceae in nursing homes in the Kinki region of Japan. Infect Drug Resist 2013; 6: 67–70. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B137] 137. Takano C, Seki M, Shiihara Het al. Frequent isolation of extended-spectrum β-lactamase-producing bacteria from fecal samples of individuals with severe motor and intellectual disabilities. J Infect Chemother 2018; 24: 182–7. [DOI] [PubMed] [Google Scholar]

[dlac048-B138] 138. Kawamura K, Hayashi K, Matsuo Net al. Prevalence of CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli B2-O25-ST131 H30R among residents in nonacute care facilities in Japan. Microb Drug Resist 2018; 24: 1513–20. [DOI] [PubMed] [Google Scholar]

[dlac048-B139] 139. Baljin B, Baldan G, Chimeddorj Bet al. Faecal carriage of Gram-negative multidrug-resistant bacteria among patients hospitalized in two centres in Ulaanbaatar, Mongolia. PLoS One 2016; 11: e0168146. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B140] 140. Mo Y, Seah I, Lye PSPet al. Relating knowledge, attitude and practice of antibiotic use to extended-spectrum β-lactamase-producing Enterobacteriaceae carriage: results of a cross-sectional community survey. BMJ Open 2019; 9: e023859. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B141] 141. Joo E-J, Kim SJ, Baek Met al. Fecal carriage of antimicrobial-resistant Enterobacteriaceae in healthy Korean adults. J Microbiol Biotechnol 2018; 28: 1178–84. [DOI] [PubMed] [Google Scholar]

[dlac048-B142] 142. Wu P-C, Wang J-L, Hsueh P-Ret al. Prevalence and risk factors for colonization by extended-spectrum β-lactamase-producing or ST 131 Escherichia coli among asymptomatic adults in community settings in Southern Taiwan. Infect Drug Resist 2019; 12: 1063–71. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B143] 143. Huang Y-S, Lai L-C, Chen Y-Aet al. Colonization with multidrug-resistant organisms among healthy adults in the community setting: prevalence, risk factors, and composition of gut microbiome. Front Microbiol 2020; 11: 1402. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B144] 144. Thi Quynh Nhi L, Thanh Tuyen H, Duc Trung Pet al. Excess body weight and age associated with the carriage of fluoroquinolone and third-generation cephalosporin resistance genes in commensal Escherichia coli from a cohort of urban Vietnamese children. J Med Microbiol 2018; 67: 1457–66. [DOI] [PubMed] [Google Scholar]

[dlac048-B145] 145. Thuy DB, Campbell J, Nhat LTHet al. Hospital-acquired colonization and infections in a Vietnamese intensive care unit. PLoS One 2018; 13: e0203600. [DOI] [PMC free article] [PubMed] [Google Scholar]

[dlac048-B146] 146. UNSD . Methodology. https://unstats.un.org/unsd/methodology/m49/.

PERMALINK

Comparison of the global prevalence and trend of human intestinal carriage of ESBL-producing Escherichia coli between healthcare and community settings: a systematic review and meta-analysis

Yihienew M Bezabih

Alemayehu Bezabih

Michel Dion

Eric Batard

Samson Teka

Abiy Obole

Noah Dessalegn

Alelegn Enyew

Anna Roujeinikova

Endalkachew Alamneh

Corinne Mirkazemi

Gregory M Peterson

Woldesellassie M Bezabhe

Abstract

Objectives

Methods

Results

Conclusions

Introduction

Methods

Data sources and search terms

Study selection: inclusion and exclusion criteria

Figure 1.

Data extraction and quality control

Data analysis

Results

Study characteristics and quality assessment

Figure 2.

Comparison of global and regional prevalence in faecal ESBL E. coli carriage between the community and healthcare settings

Figure 3.

Global and regional trends in prevalence of human intestinal ESBL E. coli carriage

Figure 4.

Analysis of correlation between human intestinal ESBL E. coli carriage rates and duration of stay in healthcare setting

Figure 5.

Discussion

Conclusions

Supplementary Material

Acknowledgements

Funding

Transparency declarations

Data sharing

Supplementary data

References

Associated Data

Supplementary Materials

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases